var title_f31_63_32752="Peripheral IV placement 8";
var content_f31_63_32752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral IV placement: Completion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The photograph above shows a peripheral IV catheter in place and secured with tape.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Frank, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32752=[""].join("\n");
var outline_f31_63_32752=null;
var title_f31_63_32753="Clinical features bilateral DDH";
var content_f31_63_32753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Clinical features of bilateral developmental dysplasia of the hips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical features of bilateral developmental dysplasia of the hips include a wide perineum (because of lateral displacement of the femoral heads and neck) and hyperlordosis (because of superior and posterior displacement of the femoral heads and neck).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32753=[""].join("\n");
var outline_f31_63_32753=null;
var title_f31_63_32754="Patient information: Croup (The Basics)";
var content_f31_63_32754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15390\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/23/29044\">",
"         Lungs in a healthy child",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/31/27121\">",
"          Signs of severe trouble breathing (retractions)",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/7/13427\">",
"         Patient information: Cough in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/57/914\">",
"         Patient information: Sore throat in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/28/2500\">",
"         Patient information: Croup in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Croup (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/croup-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H474861974\">",
"      <span class=\"h1\">",
"       What is croup?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Croup&rdquo; is the term doctors use for a group of infections that affect the trachea, the main airway through which we breathe (",
"      <a class=\"graphic graphic_figure graphicRef56535 \" href=\"mobipreview.htm?28/23/29044\">",
"       figure 1",
"      </a>",
"      ). Croup most often affects children between 6 months and 3 years of age. It causes a cough that sounds like a seal barking. In most children, croup goes away on its own. But some children with croup need to be seen by a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H474861981\">",
"      <span class=\"h1\">",
"       What are the symptoms of croup?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Croup usually begins like a regular cold. Children who get croup, start off by getting a runny nose and feeling stuffed up. A day or two later, they usually:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get a cough that sounds like a seal barking or a frog croaking",
"       </li>",
"       <li>",
"        Become hoarse (lose their voice or get a scratchy voice)",
"       </li>",
"       <li>",
"        Get a fever (temperature greater than 100.4&ordm;F or 38&ordm;C)",
"       </li>",
"       <li>",
"        Start making a whistling noise when they breathe (wheezing), especially when they are moving around.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The symptoms are usually worse at night. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H474861988\">",
"      <span class=\"h1\">",
"       Should I take my child to see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many children with croup do not need to see a doctor. But you should watch for some important symptoms.",
"     </p>",
"     <p>",
"      <strong>",
"       Call 9-1-1",
"      </strong>",
"      for an ambulance if your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Starts to turn blue or very pale",
"       </li>",
"       <li>",
"        Has a very hard time breathing",
"       </li>",
"       <li>",
"        Can&rsquo;t speak or cry because he or she can't get enough air",
"       </li>",
"       <li>",
"        Is very upset",
"       </li>",
"       <li>",
"        Seems very sleepy or does not seem to respond to you",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call your child&rsquo;s doctor or nurse if you have any questions or concerns about your child, or if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your child&rsquo;s cough won&rsquo;t go away",
"       </li>",
"       <li>",
"        Your child starts to drool or can't swallow",
"       </li>",
"       <li>",
"        Your child makes a noisy, high-pitched sound when breathing even while just sitting or resting",
"       </li>",
"       <li>",
"        The skin and muscles between your child&rsquo;s ribs or below your child&rsquo;s ribcage look like they are caving in (",
"        <a class=\"graphic graphic_figure graphicRef59786 \" href=\"mobipreview.htm?26/31/27121\">",
"         figure 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Your infant younger than 3 months has a fever (temperature greater than 100.4&ordm;F or 38&ordm;C)",
"       </li>",
"       <li>",
"        Your child older than three months has a fever (temperature greater than 100.4&ordm;F or 38&ordm;C) for more than 3 days",
"       </li>",
"       <li>",
"        Your child has symptoms of croup that last for more than 7 days",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H474862002\">",
"      <span class=\"h1\">",
"       How is croup treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatments for croup are aimed at making sure that your child is getting enough oxygen. To do that, the doctor or nurse may give your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Moist air or oxygen to breathe",
"       </li>",
"       <li>",
"        Medicines to reduce swelling or open up the airways",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The doctor will probably not offer antibiotics, because croup is caused by viruses, and antibiotics do not work on viruses.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H474862009\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to help my child feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a humidifier in your child's bedroom, or sit in the bathroom with your child while the hot water is running in the shower",
"       </li>",
"       <li>",
"        Treat your child's fever with non-prescription medicines, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sold as Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Advil&reg; or Motrin&reg;). Never give",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        to a child younger than 18 years old.",
"       </li>",
"       <li>",
"        If your child is older than 12 months, feed him or her warm, clear liquids to soothe the throat and to help loosen mucus",
"       </li>",
"       <li>",
"        Prop your child's head up on pillows or with the help of a car seat. Do not use pillows if your child is younger than 12 months old.",
"       </li>",
"       <li>",
"        Sleep in the same room as your child, so that you know right away if he or she starts having trouble breathing",
"       </li>",
"       <li>",
"        Not allow anyone to smoke near your child",
"       </li>",
"       <li>",
"        Make sure your child gets enough fluids",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H474862016\">",
"      <span class=\"h1\">",
"       How did my child get croup?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Croup is caused by viruses that spread easily from person to person. These viruses live in the droplets that go into the air when a sick person coughs or sneezes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H474862023\">",
"      <span class=\"h1\">",
"       Can croup be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce the chances that your child will get croup by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Washing your hands and your child&rsquo;s hands often with soap and water, or using alcohol hand rubs.",
"       </li>",
"       <li>",
"        Staying away from other adults and children who are sick.",
"       </li>",
"       <li>",
"        Making sure your child gets all the recommended vaccines, including the flu shot. Get a flu shot for yourself, too.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H474862030\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/57/914?source=see_link\">",
"       Patient information: Sore throat in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13427?source=see_link\">",
"       Patient information: Cough in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/28/2500?source=see_link\">",
"       Patient information: Croup in infants and children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/63/32754?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15390 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32754=[""].join("\n");
var outline_f31_63_32754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474861974\">",
"      What is croup?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474861981\">",
"      What are the symptoms of croup?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474861988\">",
"      Should I take my child to see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474862002\">",
"      How is croup treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474862009\">",
"      Is there anything I can do on my own to help my child feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474862016\">",
"      How did my child get croup?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474862023\">",
"      Can croup be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H474862030\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15390\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/23/29044\">",
"      Lungs in a healthy child",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/31/27121\">",
"       Signs of severe trouble breathing (retractions)",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/28/2500?source=related_link\">",
"      Patient information: Croup in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/57/914?source=related_link\">",
"      Patient information: Sore throat in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_63_32755="Raxibacumab: Drug information";
var content_f31_63_32755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Raxibacumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/48/7939?source=see_link\">",
"    see \"Raxibacumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15826184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16235240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anthrax, prophylaxis or treatment:",
"     </b>",
"     I.V.: 40 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Administer diphenhydramine 25-50 mg (may administer oral or I.V. depending on the proximity to start of raxibacumab infusion) &le;1 hour prior to administration of raxibacumab to reduce the risk of infusion reactions.  Must be administered in combination with antimicrobial therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F16235239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anthrax, prophylaxis or treatment:",
"     </b>",
"     Children and Adolescents: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Administer diphenhydramine (may administer oral or I.V. depending on the proximity to start of raxibacumab infusion) &le;1 hour prior to administration of raxibacumab to reduce the risk of infusion reactions.  Must be administered in combination with antimicrobial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &le;15 kg: 80 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;15 kg to 50 kg: 60 mg/kg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;50 kg: 40 mg/kg as a single dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16235241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16235242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. However, dosage adjustment unlikely as clearance is nonrenal.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16235243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16243478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 50 mg/mL (34 mL) [contains polysorbate 80, sucrose 10 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16234640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F16234633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Raxibacumab is not available for general public use. All supplies are currently owned by the federal government for inclusion in the Strategic National Stockpile and for use by the U.S. military.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16235258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Premedicate with diphenhydramine &le;1 hour prior to raxibacumab infusion. Administer over 2 hours and 15 minutes; administration rate should be slower over the first 20 minutes to monitor for adverse reactions; slow or interrupt infusion if adverse reactions (including infusion-related reactions) occur.  Administer as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Body weight: &le;1 kg: Infuse at 0.5 mL/hour for 20 minutes; increase rate to 3.5 mL/hour for the remaining infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Body weight 1.1 to 2 kg: Infuse at 1 mL/hour for 20 minutes; increase rate to 7 mL/hour for the remaining infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Body weight 2.1 to 3 kg: Infuse at 1.2 mL/hour for 20 minutes; increase rate to 10 mL/hour for the remaining infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Body weight 3.1 to 4.9 kg: Infuse at 1.5 mL/hour for 20 minutes; increase rate to 12 mL/hour for the remaining infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Body weight 5 to 10 kg: Infuse at 3 mL/hour for 20 minutes; increase rate to 25 mL/hour for the remaining infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Body weight 11 to 30 kg: Infuse at 6 mL/hour for 20 minutes; increase rate to 50 mL/hour for the remaining infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Body weight &ge;31 kg: Infuse at 15 mL/hour for 20 minutes; increase rate to 125 mL/hour for the remaining infusion",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15826186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of inhalational anthrax  following exposure to",
"     <i>",
"      Bacillus anthracis",
"     </i>",
"     in combination with appropriate antimicrobial therapy; prophylaxis of inhalational anthrax when alternative therapies are unavailable or not appropriate",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16235179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Local: Infusion-related rash (22% [without diphenhydramine premedication]; ~3% [with diphenhydramine premedication])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1.5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1.5% (Limited to important or life-threatening): Amylase increased, anemia, back pain, creatinine phosphokinase increased, fatigue, flushing, hypertension, insomnia, leukopenia, lymphadenopathy, muscle spasm, pain (infusion site), palpitations, peripheral edema, prothrombin time increased, somnolence, syncope (vasovagal), vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16234682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16234683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infusion reactions: Infusion-related reactions (eg, rash, urticaria, pruritus) have been reported.  Premedication with diphenhydramine is recommended to reduce the risk. The administration rate is slowed over the first 20 minutes to monitor for adverse reactions; slow or interrupt infusion if adverse reactions (including infusion-related reactions) occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Anthrax prophylaxis and treatment: Raxibacumab is not an antimicrobial agent; use should always be in combination with appropriate antimicrobial therapy.  Raxibacumab does not cross the blood brain barrier and is not appropriate for the prevention or treatment of meningitis due to anthrax infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Efficacy: The efficacy of raxibacumab in humans is presumptive and based solely on efficacy studies in animals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16369099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16369097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16234656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16234660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16234673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16234679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, an increase in maternal immunoglobulins is not observed in infants following nursing. The potential effects of raxibacumab on a nursing infant are not known.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16235221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Raxibacumab is a recombinant human IgG1 lambda monoclonal antibody which binds and neutralizes free protective antigen (PA) component of",
"     <i>",
"      Bacillus anthracis",
"     </i>",
"     toxin; as a result, PA-mediated delivery of lethal toxin and edema toxin via the anthrax toxin receptor (ATR) into host cells of anthrax-infected individuals is inhibited.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16235223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.07 L/kg (Migone, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: 20-22 days (Migone, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Nonrenal (Migone, 2009)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32755/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazumdar S, &ldquo;Raxibacumab,&rdquo;",
"      <i>",
"       MAbs",
"      </i>",
"      , 2009, 1(6):531-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32755/abstract-text/20068396/pubmed\" id=\"20068396\" target=\"_blank\">",
"        20068396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Migone TS, Subramanian GM, Zhong J, et al, &ldquo;Raxibacumab for the Treatment of Inhalational Anthrax,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(12):135-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32755/abstract-text/19587338/pubmed\" id=\"19587338\" target=\"_blank\">",
"        19587338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87468 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32755=[""].join("\n");
var outline_f31_63_32755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826184\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235240\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235239\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235241\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235242\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235243\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16243478\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16234640\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16234633\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235258\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826186\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235179\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16234682\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16234683\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369099\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369097\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16234656\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16234660\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16234673\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16234679\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235221\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16235223\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/48/7939?source=related_link\">",
"      Raxibacumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_63_32756="Female pelvic muscles";
var content_f31_63_32756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Female pelvic muscles at the level of the pelvic floor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the muscles of the floor of the female pelvis. Note the close proximity of the rectum to the vagina, the anococcygeal ligament that holds the rectum to the sacrum, and the pubococcygeus muscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32756=[""].join("\n");
var outline_f31_63_32756=null;
var title_f31_63_32757="Pentazocine and naloxone: Drug information";
var content_f31_63_32757=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentazocine and naloxone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/36/40516?source=see_link\">",
"    see \"Pentazocine and naloxone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9499977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9500006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Analgesic, Opioid Partial Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9500053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Analgesia:",
"     </b>",
"     Oral: Dose based on pentazocine component: 50 mg every 3-4 hours; may increase to 100 mg/dose if needed, but should not exceed 600 mg/day (maximum: 12 tablets/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9500052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Analgesia:",
"     </b>",
"     Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9500054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution; may be more sensitive to analgesic and sedative effects; decrease initial dose when appropriate and monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9500055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling does not contain renal dosing adjustment guidelines for pentazocine; the following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of normal dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9500056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9500069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Pentazocine 50 mg and naloxone 0.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9500004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F9499980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9500008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate-to-severe pain; indicated for oral use only",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9499978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9500017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Circulatory depression, facial edema, flushing, hyper-/hypotension, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, CNS depression, confusion, disorientation, dizziness, drowsiness, euphoria, excitement, hallucinations, headache, intracranial pressure increased, insomnia, irritability, lightheadedness, nightmares, sedation, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dermatitis, erythema multiforme, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distress, anorexia, biliary tract spasm, constipation, diarrhea, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), eosinophilia, WBCs decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, physical and psychological dependence, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9500013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pentazocine, naloxone, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9500014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Confusion, disorientation, and visual hallucinations have occurred in some patients, but usually clears within a few hours; observe patients closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, cholecystitis; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bowel disease: Use with caution in patients with inflammatory or obstructive bowel disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution due to the potential for increased risk of CNS depressant effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Use with caution in patients with acute MI or MI with nausea/vomiting; hypertension may occur with pentazocine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with a history of porphyria; may exacerbate condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture, especially when combined with medications that have anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedatives, including narcotics  or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose when appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: Pentazocine clearance may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Intended for oral administration only - severe vascular reactions have resulted from misuse by injection.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms; taper dose to decrease risk of withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9500020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Mixed Agonist / Antagonist Opioids may diminish the analgesic effect of Analgesics (Opioid).  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9500044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9500009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9500010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9500011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentazocine enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9500012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9500058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain, respiratory and mental status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9500047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentazocine: Agonist of kappa opiate receptors and partial agonist of mu opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces analgesia, respiratory depression and sedation similar to opioids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Naloxone: Pure opioid antagonist that competes for and displaces narcotics at opioid receptor sites in CNS. Lacks pharmacologic activity following oral administration (low dose: 0.5 mg) due to poor systemic absorption. Inhibits the actions of pentazocine when administered parenterally.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9500049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, 19.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Challoner KR, McCarron MM, and Newton EJ, &ldquo;Pentazocine (Talwin&reg;) Intoxication: Report of 57 Cases,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1990, 8(1):67-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32757/abstract-text/2351801/pubmed\" id=\"2351801\" target=\"_blank\">",
"        2351801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32757/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed DA and Schnoll SH, &ldquo;Abuse of Pentazocine-Naloxone Combination,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1986, 256(18):2562-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32757/abstract-text/3773159/pubmed\" id=\"3773159\" target=\"_blank\">",
"        3773159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9526 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32757=[""].join("\n");
var outline_f31_63_32757=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9499977\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500006\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500053\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500052\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500054\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500055\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500056\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500069\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500004\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9499980\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500008\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9499978\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500017\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500013\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500014\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299849\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500020\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500044\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500009\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500010\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500011\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500012\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500058\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500047\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9500049\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9526\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9526|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/36/40516?source=related_link\">",
"      Pentazocine and naloxone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_63_32758="Management of allergic contact dermatitis";
var content_f31_63_32758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of allergic contact dermatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32758/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32758/contributors\">",
"     Bruce A Brod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32758/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32758/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32758/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32758/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/63/32758/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 21, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6508771\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic contact dermatitis (ACD) is commonly encountered by the practicing clinician. The most common clinical expression is an eczematous dermatitis which can be mild to severe, acute and short lived, or chronic. The management of ACD is based upon the identification of the offending allergen, avoidance of exposure, use of safe alternatives, and treatment of symptoms.",
"   </p>",
"   <p>",
"    This topic will discuss the management of ACD. The basic mechanisms, clinical manifestations, and diagnosis of ACD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7223?source=see_link\">",
"     \"Basic mechanisms and pathophysiology of allergic contact dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11943?source=see_link\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/31/28150?source=see_link\">",
"     \"Patch testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6233164\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of ACD requires a multipronged approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identification and avoidance of the offending allergen",
"     </li>",
"     <li>",
"      Alternatives to offending products",
"     </li>",
"     <li>",
"      Treatment of skin inflammation",
"     </li>",
"     <li>",
"      Restoration of the skin barrier",
"     </li>",
"     <li>",
"      Skin protection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The identification of the offending allergen is a key step in the management of ACD. Although the offending allergen is often identified through a detailed history, patch testing may be necessary to identify specific antigens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11943?source=see_link&amp;anchor=H111504337#H111504337\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\", section on 'History'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/31/28150?source=see_link\">",
"     \"Patch testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6508906\">",
"    <span class=\"h1\">",
"     AVOIDANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education of patients on avoidance of offending substances and recommendation of alternative, allergen-free products are a critical part of the management of patients with ACD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75408236\">",
"    <span class=\"h2\">",
"     Common contact allergens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75408200\">",
"    <span class=\"h3\">",
"     Plants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The avoidance measures for contact allergy to plants of the",
"    <em>",
"     Toxicodendron",
"    </em>",
"    genus (poison ivy, oak, and sumac) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/44/20168?source=see_link&amp;anchor=H9#H9\">",
"     \"Poison ivy (Toxicodendron) dermatitis\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75408207\">",
"    <span class=\"h3\">",
"     Nickel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nickel is found in alloys and plated objects, including jewelry, buttons, zippers, coins, keys, scissors, and metal tools. Providing nickel-sensitive patients with a list of objects that may contain nickel may be helpful. A nickel test kit (eg, Spot Test for Nickel, Delasco",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) may also be useful for patients to identify nickel-releasing objects at home or at work. These kits, which use dimethylglyoxime, do not harm the object being tested. In one study, the nickel spot test had a sensitivity and specificity of 60 and 98 percent, respectively, in detecting nickel released in amounts &gt;0.5",
"    <span class=\"nowrap\">",
"     microg/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week by a set of earrings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/2\">",
"     2",
"    </a>",
"    ]. This is the threshold established by the European Union Nickel Directive for products intended to be in direct and prolonged contact with the skin.",
"   </p>",
"   <p>",
"    Since jewelry (including some yellow and white gold jewelry) and metal components of clothing are the most common sources of nickel that are in prolonged contact with the skin, several avoidance measures have been suggested to limit nickel exposure from these sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coating a nickel object with a physical barrier may prevent the release of nickel ions. The application of a nail polish to the buttons and rivets of jeans may prevent nickel release through at least two wash and dry cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/4\">",
"     4",
"    </a>",
"    ]. As an alternative, iron-on patches may be applied on clothes to cover metal parts that come in contact with the skin. Another physical barrier is duct tape. This can adhere to the inside of buttons or snaps, is inexpensive, easy to apply, and widely available.",
"   </p>",
"   <p>",
"    Chemical barriers for nickel include chelating and non-chelating barrier creams. Barrier creams containing agents such as disodium ethylenediamine tetra-acetate (EDTA) act by chelating the positive ionic charge and rendering the metal inactive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Non-chelating creams may prevent the penetration of nickel through the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75408214\">",
"    <span class=\"h3\">",
"     Cosmetics and personal care products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cosmetics and personal care products contain a high number of chemical ingredients, only a few of them are responsible for most cases of ACD. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fragrances",
"     </li>",
"     <li>",
"      Preservatives (eg, quaternium-15, parabens,",
"      <span class=\"nowrap\">",
"       MCI/MI",
"      </span>",
"      [the combination of methylchloroisothiazolinone and methylisothiazolinone, which is marketed as Kathon CG or Kathon WT], thimerosal)",
"     </li>",
"     <li>",
"      Excipients (eg, propylene glycol, lanolin, or colorants)",
"     </li>",
"     <li>",
"      Glues (eg, acrylates in nail products)",
"     </li>",
"     <li>",
"      Sunscreens",
"     </li>",
"     <li>",
"      Hair dyes (para-phenylenediamine and derivatives)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Learning to read the labels of cosmetic or personal care products is important for patients with ACD. Information on specific ingredients in personal care or household products commercialized in the United States can be found in the Household Product Database of the United States National Library of Medicine at",
"    <a class=\"external\" href=\"file://hpd.nlm.nih.gov/index.htm\">",
"     hpd.nlm.nih.gov/index.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6233243\">",
"    <span class=\"h2\">",
"     Alternative products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians may obtain information on alternative products for allergic patients from several sources. The Contact Allergen Management Program (CAMP) of the American Contact Dermatitis Society (ACDS) (",
"    <a class=\"external\" href=\"file://www.contactderm.org/\">",
"     www.contactderm.org",
"    </a>",
"    ), which requires membership, allows the clinician to create an individualized list of products, including gloves, that are free of specific allergens. The Contact Allergen Replacement Database (CARD)",
"    <span class=\"nowrap\">",
"     www.preventice.com/card",
"    </span>",
"    is another resource for alternative products.",
"   </p>",
"   <p>",
"    The American Contact Alternative Group provides an extensive list of alternatives for the allergens included in the 2007 North American Contact Dermatitis Group (NACDG) standard tray [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/8\">",
"     8",
"    </a>",
"    ]. Specific lists of alternatives for facial cosmetics and hair products containing few or none of the allergens included in the standard series of the American Contact Dermatitis Society are also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26565598\">",
"    <span class=\"h2\">",
"     Occupational avoidance measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance in the workplace requires a more complex strategy. Several general measures may be adopted in the workplace to reduce exposure to chemicals, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Substitution of safer alternatives for allergenic materials",
"     </li>",
"     <li>",
"      Automation",
"     </li>",
"     <li>",
"      Process enclosure",
"     </li>",
"     <li>",
"      Use of equipment for handling substances",
"     </li>",
"     <li>",
"      Keeping a safe working distance",
"     </li>",
"     <li>",
"      Washing promptly any chemical exposures from the skin",
"     </li>",
"     <li>",
"      Using protective clothing and gloves",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Protective gloves can reduce or eliminate exposure of the hands to hazardous substances. Gloves are ideally selected on the basis of the glove permeation and degradation properties and nature of the compounds that are manipulated. Multilayer laminate gloves, which incorporate a",
"    <span class=\"nowrap\">",
"     hydrophilic/polar",
"    </span>",
"    layer between two",
"    <span class=\"nowrap\">",
"     hydrophobic/non-polar",
"    </span>",
"    layers, usually provide a high level of protection against a wide range of chemicals. However, gloves, particularly rubber gloves, contain allergens that may worsen hand dermatitis in some patients.",
"   </p>",
"   <p>",
"    Additional information on protective equipment for chemical exposures is available at",
"    <a class=\"external\" href=\"file://www.kristerforsberg.com/cpc/\">",
"     www.kristerforsberg.com/cpc/",
"    </a>",
"    or",
"    <a class=\"external\" href=\"file://naples.cc.sunysb.edu/admin/hrsforms.nsf/pub/ehsd0058/$file/ehsd0058.pdf\">",
"     naples.cc.sunysb.edu/Admin/HRSForms.nsf/pub/EHSD0058/$File/EHSD0058.pdf",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Education on the proper way to put on and take off gloves is required to minimize exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320147\">",
"    <span class=\"h2\">",
"     Skin protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant contact dermatitis is often associated with or precedes the development of ACD. Prework (barrier) creams and after-work (emollients) creams appear to confer some degree of protection against irritant contact dermatitis, although evidence from randomized trials is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/12\">",
"     12",
"    </a>",
"    ]. The substitution of milder detergents for abrasive or irritating cleansers and the application of allergen-free emollients (eg, petrolatum-based emollients) after each hand washing may reduce the risk of hand dermatitis at the workplace [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The regular application of emollients to normal skin after repeated exposure to irritants may help to maintain the skin barrier function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/14\">",
"     14",
"    </a>",
"    ]. Emollients may be liberally used as an adjunct to corticosteroids in the treatment of ACD, particularly chronic, lichenified dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6508920\">",
"    <span class=\"h1\">",
"     ACTIVE TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1039422426\">",
"    <span class=\"h2\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although avoidance of the offending allergen is the mainstay of management of ACD, treatment is required in most cases to achieve rapid control of symptoms. The treatment of ACD follows the general principles of eczema treatment and includes: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Topical corticosteroids",
"      </strong>",
"      &mdash; Topical corticosteroids are the first line treatment for localized ACD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/7,13\">",
"       7,13",
"      </a>",
"      ]. Their efficacy in the treatment of ACD has not been evaluated in randomized trials. However, their efficacy in other forms of eczematous dermatitis has been demonstrated in a systematic review of randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of atopic dermatitis (eczema)\", section on 'Corticosteroids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Topical calcineurin inhibitors",
"      </strong>",
"      &mdash; Topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      may be an alternative to topical corticosteroids in the management of chronic, localized ACD; localized ACD resistant to topical corticosteroids; ACD involving the face or intertriginous areas; and ACD induced by topical corticosteroids.",
"      <br/>",
"      <br/>",
"      The efficacy of topical tacrolimus in ACD has been evaluated in randomized trials of experimentally induced, nickel contact dermatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. In one study, tacrolimus 0.1% ointment applied twice daily was more effective than placebo in clearing the eruption over eight weeks of continued exposure to the allergen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are no high quality studies comparing topical calcineurin inhibitors with topical corticosteroids in ACD. The onset of action of tacrolimus is slower than for potent topical corticosteroids. Local side effects of topical calcineurin inhibitors include burning and stinging at the site of application. Additional side effects of topical calcineurin inhibitors are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of atopic dermatitis (eczema)\", section on 'Topical calcineurin inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other topical treatments",
"      </strong>",
"      &mdash; Soothing and drying agents may be useful for reduction of discomfort and pruritus in acute ACD. These include aluminum acetate compresses,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/11/33969?source=see_link\">",
"       calamine lotion",
"      </a>",
"      , and colloidal oatmeal compresses or baths.",
"     </li>",
"     <li>",
"      <strong>",
"       Systemic corticosteroids",
"      </strong>",
"      &mdash; Oral corticosteroids are the first line treatment for ACD involving &gt;20 percent of the body surface area or for acute ACD involving the face, hands, feet or genitalia if quick relief is desired (eg, involvement of the eyelids) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/7\">",
"       7",
"      </a>",
"      ]. Oral corticosteroids for ACD have not been studied in randomized trials. However, in clinical experience they are frequently beneficial in the treatment of poison ivy dermatitis, a common form of ACD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/44/20168?source=see_link&amp;anchor=H19#H19\">",
"       \"Poison ivy (Toxicodendron) dermatitis\", section on 'Systemic corticosteroids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Phototherapy",
"      </strong>",
"      &mdash; Phototherapy is a therapeutic option in patients with chronic ACD that is unresponsive to topical or oral corticosteroids. Small observational studies of patients with chronic hand eczema of various etiologies demonstrated clinical improvement with PUVA or narrow-band UVB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. Narrowband UVB is more convenient for the patient and associated with fewer side effects than PUVA.",
"     </li>",
"     <li>",
"      <strong>",
"       Systemic immunosuppressive agents",
"      </strong>",
"      &mdash; Rarely, in cases of chronic ACD,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      have been used. Situations such as airborne compositae dermatitis or photodermatitis, where allergen avoidance is impossible, are examples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23871208\">",
"    <span class=\"h2\">",
"     ACD involving the face or flexural areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest medium or low-potency (groups five and six (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) topical corticosteroids for ACD of the face and flexural areas. Topical corticosteroids are applied once or twice daily for one to two weeks.",
"   </p>",
"   <p>",
"    Systemic corticosteroids may be required for acute ACD involving the face if topical corticosteroids are ineffective or if quick relief is desired (eg, for eyelid involvement). Treatment is started with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or equivalent dose of other systemic corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"     table 2",
"    </a>",
"    )) at a dose of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for seven days. The dose may be reduced by 50 percent in the next five to seven days and then tapered and discontinued over the following two weeks.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    is an alternative to topical corticosteroids in the management of ACD involving the face or intertriginous areas. Tacrolimus 0.1% ointment or pimecrolimus 1% cream is applied twice daily until resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23871295\">",
"    <span class=\"h2\">",
"     ACD involving the hands, feet, or nonflexural areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest high potency (group one to three (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) topical corticosteroids for treatment of ACD that does not involve the face or flexural areas. Topical corticosteroids are applied once or twice daily for two to four weeks, or until resolution of symptoms.",
"   </p>",
"   <p>",
"    If the dermatitis is acute and weeping, topical corticosteroids may be used in combination with drying agents (eg, aluminum acetate soaks).",
"   </p>",
"   <p>",
"    We suggest oral corticosteroids as the first line treatment for ACD involving &gt;20 percent of the body surface area, or when localized ACD is disabling, as with ACD of the hands, feet or genitalia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/7\">",
"     7",
"    </a>",
"    ]. Treatment is started with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or equivalent dose of other systemic corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"     table 2",
"    </a>",
"    )) at a dose of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for seven days. The dose may be reduced by 50 percent in the next five to seven days and then tapered and discontinued over the following two weeks. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Topical calcineurin inhibitors are an alternative to topical corticosteroids in the management of localized ACD resistant to topical corticosteroids and ACD induced by topical corticosteroids. Topical calcineurin inhibitors are applied twice daily until resolution.",
"   </p>",
"   <p>",
"    Phototherapy and the other systemic agents mentioned above may also be useful. (See",
"    <a class=\"local\" href=\"#H1039422426\">",
"     'Treatment approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1039422539\">",
"    <span class=\"h3\">",
"     Chronic ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest intermittent high potency (group one to three (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) topical corticosteroids for long-term control of chronic ACD involving the hands, feet, or nonflexural areas. In a randomized trial, 120 patients with chronic hand eczema initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    furoate 0.1% fatty cream for up to nine weeks or until the dermatitis cleared, were randomly assigned to a 30-week maintenance period with intermittent mometasone furoate (once daily on Sunday, Tuesday, and Thursday or on Saturday and Sunday) or vehicle. Mometasone furoate applied three times weekly was more effective than vehicle in preventing recurrence of dermatitis (83 versus 26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32758/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breakdown of the skin barrier (atrophy) is a complicating factor in many cases of chronic ACD, which is exacerbated by overuse of topical corticosteroids. Every effort should be made to minimize continuous use of these agents beyond two to four weeks.",
"   </p>",
"   <p>",
"    Topical calcineurin inhibitors may be an alternative to topical corticosteroids in the management of chronic localized ACD resistant to topical corticosteroids and ACD induced by topical corticosteroids. They may be particularly useful in &ldquo;sensitive-skin&rdquo; locations (eg, the face or intertriginous areas). However, topical calcineurin inhibitors are expensive and there is little evidence to determine the optimal regimen. We suggest that calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1% ointment or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    1% cream) be applied twice daily to affected areas until resolution. They can be restarted if there is a recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H320159\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of allergic contact dermatitis (ACD) consists of the identification of the offending allergen, avoidance, and treatment of skin inflammation. (See",
"      <a class=\"local\" href=\"#H6233164\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Education about avoidance of offending substances and recommendations for alternative, allergen-free products are a critical part of the management of patients with ACD. (See",
"      <a class=\"local\" href=\"#H6508906\">",
"       'Avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest medium or low-potency (groups five and six (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) topical corticosteroids for ACD of the face and flexural areas that is not disabling (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical corticosteroids are applied once or twice daily for one to two weeks. Topical calcineurin inhibitors are an alternative. Topical calcineurin inhibitors are applied twice daily until resolution. (See",
"      <a class=\"local\" href=\"#H23871208\">",
"       'ACD involving the face or flexural areas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest high potency (group one to three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) topical corticosteroids for treatment of ACD that involves &lt;20 percent of the body surface area, does not involve the face or flexural areas, and is not disabling (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical corticosteroids are applied once or twice daily for two to four weeks, or until resolution of symptoms. Topical calcineurin inhibitors are an alternative. (See",
"      <a class=\"local\" href=\"#H23871295\">",
"       'ACD involving the hands, feet, or nonflexural areas'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest systemic rather than topical corticosteroids for:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute and extensive ACD involving the face if topical corticosteroids are ineffective or if quick relief is desired (eg, for eyelid involvement) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23871208\">",
"       'ACD involving the face or flexural areas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACD that involves &gt;20 percent of the body surface area (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23871295\">",
"       'ACD involving the hands, feet, or nonflexural areas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACD that involves &lt;20 percent of the body surface area and is disabling or has not responded to treatment with topical corticosteroids or calcineurin inhibitors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23871295\">",
"       'ACD involving the hands, feet, or nonflexural areas'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Treatment is started with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (or equivalent dose of other systemic corticosteroids (",
"      <a class=\"graphic graphic_table graphicRef64138 \" href=\"mobipreview.htm?41/61/42972\">",
"       table 2",
"      </a>",
"      )) at a dose of 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 60 mg per day) per day for seven days. The dose may be reduced by 50 percent in the next five to seven days and then tapered and discontinued over the following two weeks. (See",
"      <a class=\"local\" href=\"#H1039422426\">",
"       'Treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phototherapy and systemic immunosuppressive medications are therapeutic options in patients with chronic ACD that is unresponsive to topical or oral corticosteroids. Narrowband UVB is more convenient for the patient and associated with fewer side effects than PUVA. (See",
"      <a class=\"local\" href=\"#H1039422426\">",
"       'Treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest intermittent high potency (group one to three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) topical corticosteroids rather than emollients alone for long-term control of chronic ACD involving the hands, feet, or nonflexural areas (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The topical steroid is applied once daily three times per week on alternate days. Topical calcineurin inhibitors may be helpful in chronic localized ACD that is not responsive to topical corticosteroids or that is induced by topical corticosteroids. (See",
"      <a class=\"local\" href=\"#H1039422539\">",
"       'Chronic ACD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/1\">",
"      Bikowski JB. Hand eczema: diagnosis and management. Cutis 2008; 82:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/2\">",
"      Thyssen JP, Skare L, Lundgren L, et al. Sensitivity and specificity of the nickel spot (dimethylglyoxime) test. Contact Dermatitis 2010; 62:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/3\">",
"      Lu LK, Warshaw EM, Dunnick CA. Prevention of nickel allergy: the case for regulation? Dermatol Clin 2009; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/4\">",
"      Suneja T, Flanagan KH, Glaser DA. Blue-jean button nickel: prevalence and prevention of its release from buttons. Dermatitis 2007; 18:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/5\">",
"      van Ketel WG, Bruynzeel DP. Chelating effect of EDTA on nickel. Contact Dermatitis 1984; 11:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/6\">",
"      W&ouml;hrl S, Kriechbaumer N, Hemmer W, et al. A cream containing the chelator DTPA (diethylenetriaminepenta-acetic acid) can prevent contact allergic reactions to metals. Contact Dermatitis 2001; 44:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/7\">",
"      American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology. Contact dermatitis: a practice parameter. Ann Allergy Asthma Immunol 2006; 97:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/8\">",
"      Scheman A, Jacob S, Zirwas M, et al. Contact Allergy: alternatives for the 2007 North American contact dermatitis group (NACDG) Standard Screening Tray. Dis Mon 2008; 54:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/9\">",
"      Scheman A, Jacob S, Katta R, et al. Part 1 of a 4-part series Facial Cosmetics: Trends and Alternatives: Data from the American Contact Alternatives Group. J Clin Aesthet Dermatol 2011; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/10\">",
"      Scheman A, Jacob S, Katta R, et al. Part 2 of a 4-part series Hair Products: Trends and Alternatives: Data from the American Contact Alternatives Group. J Clin Aesthet Dermatol 2011; 4:42.",
"     </a>",
"    </li>",
"    <li>",
"     Forsberg K, Mansdorf SZ. Quick selection guide to chemical protective clothing, 5th ed, John Wiley and Sons, Inc., Hoboken, NJ 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/12\">",
"      Bauer A, Schmitt J, Bennett C, et al. Interventions for preventing occupational irritant hand dermatitis. Cochrane Database Syst Rev 2010; :CD004414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/13\">",
"      Bourke J, Coulson I, English J, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of contact dermatitis: an update. Br J Dermatol 2009; 160:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/14\">",
"      Williams C, Wilkinson SM, McShane P, et al. A double-blind, randomized study to assess the effectiveness of different moisturizers in preventing dermatitis induced by hand washing to simulate healthcare use. Br J Dermatol 2010; 162:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/15\">",
"      Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/16\">",
"      Belsito D, Wilson DC, Warshaw E, et al. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol 2006; 55:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/17\">",
"      Pacor ML, Di Lorenzo G, Martinelli N, et al. Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc 2006; 27:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/18\">",
"      Schempp CM, M&uuml;ller H, Czech W, et al. Treatment of chronic palmoplantar eczema with local bath-PUVA therapy. J Am Acad Dermatol 1997; 36:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/19\">",
"      van Coevorden AM, Kamphof WG, van Sonderen E, et al. Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy. Arch Dermatol 2004; 140:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/20\">",
"      Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed 2007; 23:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32758/abstract/21\">",
"      Veien NK, Olholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol 1999; 140:882.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13665 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32758=[""].join("\n");
var outline_f31_63_32758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H320159\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6508771\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6233164\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6508906\">",
"      AVOIDANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75408236\">",
"      Common contact allergens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75408200\">",
"      - Plants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75408207\">",
"      - Nickel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75408214\">",
"      - Cosmetics and personal care products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6233243\">",
"      Alternative products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26565598\">",
"      Occupational avoidance measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H320147\">",
"      Skin protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6508920\">",
"      ACTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1039422426\">",
"      Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23871208\">",
"      ACD involving the face or flexural areas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23871295\">",
"      ACD involving the hands, feet, or nonflexural areas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1039422539\">",
"      - Chronic ACD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H320159\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/61/42972\" title=\"table 2\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7223?source=related_link\">",
"      Basic mechanisms and pathophysiology of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11943?source=related_link\">",
"      Clinical features and diagnosis of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/31/28150?source=related_link\">",
"      Patch testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/44/20168?source=related_link\">",
"      Poison ivy (Toxicodendron) dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_63_32759="Pouchitis";
var content_f31_63_32759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pouchitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32759/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32759/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32759/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32759/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/63/32759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the surgical treatment of ulcerative colitis (UC) and familial adenomatous polyposis (FAP), proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the favored alternative to proctocolectomy with permanent ileostomy since it preserves intestinal continuity and sphincter function and removes the entire colorectal mucosa. This procedure consists of total abdominal colectomy, stripping of the rectal mucosa with preservation of the anal sphincter, and the construction of an ileal pouch that is anastomosed to the anus.",
"   </p>",
"   <p>",
"    The most frequently observed long-term complication of IPAA is acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic inflammation of the ileal reservoir, called pouchitis. This is not a well-defined entity, and much uncertainty remains regarding its true prevalence, etiology, and natural history. However, the condition continues to overshadow the overall good functional results of this sphincter-saving operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) have a higher incidence of pouchitis compared to those who undergo the procedure for FAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In patients who undergo IPAA for UC, the reported prevalence of pouchitis varies widely from less than 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/1,3-8\">",
"     1,3-8",
"    </a>",
"    ] to as high as 44 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/9\">",
"     9",
"    </a>",
"    ]. The large variations that have been reported reflect differences in diagnostic criteria and follow-up and are responsible for much of the confusion surrounding pouchitis. As an example, in one series of 149 patients, the incidence of mild pouchitis (diagnosed by symptoms and endoscopy) was 21, 26, and 39 percent at 6, 12, and 48 months; the respective values for severe pouchitis were 9, 11, and 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of pouchitis remains uncertain although preoperative and postoperative factors may contribute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Preoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors associated with acute pouchitis include use of steroids before colectomy, and a history of extensive colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Extraintestinal manifestations of colitis and primary sclerosing cholangitis are associated with an increased risk of chronic pouchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/1,10,12\">",
"     1,10,12",
"    </a>",
"    ], while smoking appears to protect against the development of acute and chronic pouchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with mutations in the gene that encodes the protein",
"    <span class=\"nowrap\">",
"     NOD2/CARD15",
"    </span>",
"    appear to be at increased risk of pouchitis following proctocolectomy with ileal pouch-anal anastomosis (IPAA). In a case-control study of 107 patients with an IPAA and 269 controls,",
"    <span class=\"nowrap\">",
"     NOD2/CARD15",
"    </span>",
"    mutations were noted in 67 percent of patients with severe pouchitis, compared with 9 percent of healthy controls, 5 percent of patients who were asymptomatic following IPAA, and 14 percent of patients with an IPAA and Crohn&rsquo;s disease-like complications (eg, perianal fistula, pouch inlet stricture, proximal small bowel disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Postoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors developing after surgery have also been proposed as contributors to pouchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/14-25\">",
"     14-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overgrowth of bacterial flora that become more anaerobic may occur because of stasis. Pouchitis has been described in patients with excessively large pouches that empty poorly and in those with anastomotic strictures which are often associated with bacterial overgrowth. However, no close relationship between reduced reservoir emptying and the incidence of pouchitis has been established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/14,24,26\">",
"       14,24,26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Bacterial overgrowth might cause pouchitis indirectly by either changing the pouch contents or by altering mucosal defense mechanisms. One theory proposes that colonic metaplasia in the pouch predisposes to growth of sulfate-reducing bacteria that produce hydrogen sulfide, which (in high concentrations) is toxic to colonocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/27\">",
"       27",
"      </a>",
"      ]. A small cross-sectional study of 32 patients with IPAA for ulcerative colitis (UC) demonstrated a direct correlation between pouch granulocyte and monocyte mucosal infiltration, colony counts of Bacteroides spp. and Clostridiaceae spp., mucosal ulceration, and the number of daily stools. Conversely, in patients with pouchitis, Enterococcaceae spp. counts were lower than in healthy subjects. Enterobacteriaceae spp., Streptococcaceae spp. and Enterococcaceae spp. counts correlated inversely with immune cell infiltration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/28\">",
"       28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The response of pouchitis to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      and other antibiotics (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis and treatment'",
"      </a>",
"      below) suggests a bacterial etiology for reservoir inflammation; however, no intestinal pathogen has been consistently incriminated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of perinuclear cytoplasmic antibodies (pANCA) is associated with the development of chronic pouchitis in 60 to 80 percent of patients. In a group of 60 pouch patients who were pANCA positive, pouchitis occurred in 56 percent of those with a high titer of pANCA (&gt;100 ELISA units) while the risk in patients with a lower titer was no greater than in pANCA negative individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The role of the fecal stream and its bacterial and biochemical composition on the reservoir has also been the subject of controversy. Serial biopsies of pouches showed that significant acute",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic inflammation, villous atrophy, and crypt hyperplasia developed only after ileostomy closure in the majority of patients, suggesting that the fecal stream plays an important role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drug consumption",
"     </li>",
"     <li>",
"      Lack of mucosal trophic factors (such as short-chain fatty acids)",
"     </li>",
"     <li>",
"      Decreased resistance of the mucosal immune system due to reduced number of intraepithelial T-lymphocytes",
"     </li>",
"     <li>",
"      Increased cytotoxicity due to bile acids",
"     </li>",
"     <li>",
"      Raised levels of platelet activating factor or oxygen-derived free radicals, caused by transient mucosal ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is based upon the presence of compatible clinical, endoscopic, and pathological features and exclusion of disorders that can produce similar features.",
"   </p>",
"   <p>",
"    Symptoms of pouchitis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased stool frequency",
"     </li>",
"     <li>",
"      Urgency",
"     </li>",
"     <li>",
"      Hematochezia",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A small proportion of patients have pre-pouch ileitis accompanying pouchitis. The disabling symptoms associated with pre-pouch ileitis are similar to pouchitis and include increased stool frequency and urgency. Pre-pouch ileitis is not a sign of Crohn's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1121783413\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions produce similar symptoms, such as outlet obstruction, specific bacterial or parasitic infections, cytomegalovirus (CMV) infection, recurrent or misdiagnosed Crohn's disease, anal stenosis, a peripouch abscess, and functional bowel syndromes such as irritable pouch syndrome (IPS).",
"   </p>",
"   <p>",
"    IPS is a functional disorder in patients with ileal pouch-anal anastomosis (IPAA), which presents with symptoms in the absence of structural abnormalities of the pouch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, it resembles functional disorders such as irritable bowel syndrome. IPS is characterized by visceral hypersensitivity in the presence of normal rectal biomechanics. Patients with IPS have severe diarrhea, abdominal pain, urgency, and pelvic pain with a normal pouchoscopy and pelvic magnetic resonance imaging (MRI). The management approach to IPS is similar to that for IBS in patients with IBD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8279?source=see_link&amp;anchor=H6829269#H6829269\">",
"     \"Irritable bowel syndrome in patients with inflammatory bowel disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who have undergone a stapled ileal pouch-anal anastomosis, cuffitis can cause symptoms mimicking pouchitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1121783420\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms alone, however, are not sufficient to define pouchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/31\">",
"     31",
"    </a>",
"    ]. The following tests may help confirm the diagnosis of pouchitis and exclude other disorders that can produce similar features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1121783427\">",
"    <span class=\"h2\">",
"     Stool markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of fecal lactoferrin concentration (a marker of neutrophil activation) has been proposed as a noninvasive initial screening test for distinguishing pouchitis from other causes of symptoms but its accuracy is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pouchitis is accompanied by endoscopic stigmata of mucosal inflammation, ie, diffuse erythema, swelling, and friability of the mucosa, and sometimes hemorrhages, erosions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulcerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/24,31\">",
"     24,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macroscopic inflammation correlates significantly with stool frequency and with extensive histologic inflammation. In most patients with lesser degrees of inflammation, mucosal lesions on endoscopy are absent and alteration in stool frequency is quite variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic evaluation can help confirm the diagnosis and help exclude cytomegalovirus (CMV) infection (which can masquerade as or complicate pouchitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Histologic features of chronic inflammation in the reservoir are much more prevalent than are acute changes (",
"    <a class=\"graphic graphic_picture graphicRef51150 \" href=\"mobipreview.htm?7/36/7750\">",
"     picture 1",
"    </a>",
"    ). In an illustrative series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less than 4 percent of patients were completely free of pouch inflammation, whereas acute and chronic inflammation was noted in 30 and 87 percent, respectively.",
"     </li>",
"     <li>",
"      Intense acute inflammation was uncommon (11 percent of patients) and found only in patients operated on for UC. There was no difference between ulcerative colitis (UC) and FAP with regard to chronic inflammation.",
"     </li>",
"     <li>",
"      Chronic inflammation of the reservoir was usually associated with villous atrophy, and was always accompanied by crypt hyperplasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalences of both acute and chronic inflammation of the reservoir mucosa vary with the duration of follow-up, and the number and sites of biopsies. This emphasizes the need for multiple biopsies. In a series of 78 patients with UC and an IPAA, with a mean follow-up of 95 months, and a mean number of biopsies per patient of 5.4 (range 1 to 13), histopathologic changes were noted in 95 percent of the specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/36\">",
"     36",
"    </a>",
"    ]. Mild and severe chronic inflammation was seen in 56 and 39 percent of the biopsy specimens, respectively. Normal mucosa was found in only 24 biopsies (5.4 percent) in 18 patients. However, previous or subsequent biopsies from the same patient always showed pathologic changes. A heterogeneous distribution of pathologic changes in the pouch was found: maximal lesions usually occur in the lower and posterior regions.",
"   </p>",
"   <p>",
"    Another common pathologic finding is partial colonic metaplasia, seen in 35 to 96 percent of patients with IPAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the large experience of the Mayo Clinic, one-half of the affected patients experienced recurrent episodes of pouchitis requiring repeated treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 10 to 20 percent of patients with pouchitis develop chronic pouchitis, defined as symptoms lasting greater than four weeks.",
"   </p>",
"   <p>",
"    Acute pouchitis is easily treated, while chronic pouchitis remains difficult to treat. Chronic pouchitis can be either responsive or refractory to treatment (",
"    <a class=\"external\" href=\"file://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2006.02884.x/pdf\">",
"     see Figure 1, \"Treatment algorithm for pouchitis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics have been shown to be effective in treating pouchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      &ndash; Oral metronidazole, at a dose of 1 to 2 g daily for seven days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/4,8\">",
"       4,8",
"      </a>",
"      ] has been used to treat pouchitis. Treatment may be most effective with acute episodes, and may be less effective with chronic disease. One double-blind cross-over trial randomly assigned patients with chronic unremitting pouchitis to metronidazole (400 mg three times daily for seven days) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/39\">",
"       39",
"      </a>",
"      ]. Metronidazole was associated with a significant reduction in stool frequency by three movements per day (versus an increase of one per day with placebo) but there was no change in the endoscopic or histologic grade of inflammation.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      &ndash; Oral ciprofloxacin at a dose of 1 g daily is an effective treatment for pouchitis, including those patients who failed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. In one study, 16 patients who were randomly assigned to either ciprofloxacin 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      or metronidazole 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day showed a response to both drugs, but had significantly better improvement and fewer side effects (0 versus 33 percent) with ciprofloxacin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/40\">",
"       40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Because of its better tolerance, we choose ciprofloxacin at 1 g daily as the initial treatment for acute pouchitis reserving metronidazole for those failing ciprofloxacin.",
"      <br/>",
"      <br/>",
"      For patients who have relapsing symptoms, we use chronic, low dose ciprofloxacin.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37140?source=see_link\">",
"       Rifaximin",
"      </a>",
"      &ndash; The nonabsorbed antibiotic rifaximin has also been used in pouchitis but was not more effective than placebo in a small controlled trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/42\">",
"       42",
"      </a>",
"      ]. However, rifaximin maintenance therapy was effective in preventing relapse in 65 percent of patients with antibiotic-dependent pouchitis after induction of remission with a variety of antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combination antibiotic approaches, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/44,45\">",
"       44,45",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      and ciprofloxacin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/46\">",
"       46",
"      </a>",
"      ], and ciprofloxacin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"       tinidazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/47\">",
"       47",
"      </a>",
"      ] have also been reported to be efficacious in the treatment of chronic refractory pouchitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fecal coliform sensitivity testing has shown to be helpful in guiding choice of effective antibiotics in patients with antibiotic-resistant pouchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/49\">",
"     49",
"    </a>",
"    ]. In this study, 80 percent of patients achieved a clinical remission with individualized therapy based on sensitivity results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Budesonide",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who fail antibiotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    may be a treatment option. Oral budesonide (9",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for eight weeks) was effective in a series of patients with acute pouchitis refractory to antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    suppositories for four weeks showed endoscopic improvement or remission at the end of the treatment in all patients with acute pouchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/51\">",
"     51",
"    </a>",
"    ]. However, 6 of 10 patients relapsed eight weeks later.",
"   </p>",
"   <p>",
"    In a controlled trial, 26 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    enemas (2 mg per 100 mL at bedtime) plus placebo tablets or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg twice daily) plus placebo enemas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/52\">",
"     52",
"    </a>",
"    ]. Both regimens were associated with similar clinical improvement but adverse effects were more common in those receiving metronidazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the microflora have been demonstrated in patients with pouchitis providing a rationale for treatments aimed at altering the flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/53\">",
"     53",
"    </a>",
"    ]. In a study of 40 patients, the probiotic preparation, VSL#3 was more effective in maintaining remission than placebo (85 versus 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/54\">",
"     54",
"    </a>",
"    ]. When VSL#3 was discontinued, all patients relapsed. In another placebo-controlled trial, more patients receiving VSL#3 remained in remission at one year compared to those receiving placebo (85 versus 6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      enemas followed by a short course of oral steroids if enemas cannot be retained can be used as a therapeutic trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      was effective long-term (20 months) in IPAA patients with refractory luminal inflammation and in three of seven patients with pouch fistulas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/57\">",
"       57",
"      </a>",
"      ]. However, risks and benefits need to be considered; and this treatment is likely reserved for patients with the most severe symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26647?source=see_link\">",
"       \"Anti-tumor necrosis factor therapy in ulcerative colitis\"",
"      </a>",
"      .) 6-mercaptopurine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      can also be considered in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURVEILLANCE FOR CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major long-term concern in patients with ileal pouch-anal anastomosis (IPAA) is the possibility that chronic inflammation of the reservoir may carry the same risk of mucosal dysplasia and cancer as does ileorectal anastomosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4906?source=see_link&amp;anchor=H14#H14\">",
"     \"Surgical management of ulcerative colitis\", section on 'Postoperative monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenocarcinoma has been observed in patients with familial adenomatous polyposis (FAP) and long-established ileostomies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The ileal mucosa transforms into a colonic-like mucosa in most patients after IPAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], and increased cell proliferation has been observed in reservoirs whether or not the patients had pouchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/60\">",
"     60",
"    </a>",
"    ]. Chronic inflammation of the reservoir mucosa is almost universally noted when the mucosa is carefully sampled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only a few studies have followed patients for more than 10 years. A report with one of the longest follow-up periods (15 to 20 years) found that the development of dysplasia was rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/61\">",
"     61",
"    </a>",
"    ]. Nevertheless, severe mucosal atrophy together with dysplastic epithelial changes and DNA aneuploidy have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. However, very few cases of cancer in the pouch of patients operated for ulcerative colitis (UC) have been described. The presence of a rectal cuff is a risk factor for cancer and the incidence of dysplasia or cancer after IPAA is strongly associated with the presence of dysplasia or cancer in the proctocolectomy specimen. Based in part upon these observations, it has been suggested that endoscopic and histopathologic surveillance of the reservoir mucosa should be undertaken in patients with IPAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32759/abstract/36,64\">",
"     36,64",
"    </a>",
"    ]. Since mucosal abnormalities might be focal, multiple biopsies would be needed.",
"   </p>",
"   <p>",
"    We support endoscopic surveillance of the pouch beginning three years after pouch construction and every three years thereafter. If severe mucosal atrophy is found, then yearly surveillance is suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pouchitis is characterized by the development of chronic inflammation associated with symptoms (urgency, tenesmus, bleeding, incontinence and increased stool frequency) in the pouch following ileal pouch-anal anastomosis (IPAA). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based upon the presence of compatible clinical, endoscopic and pathological features and exclusion of disorders that can produce similar features. The differential diagnosis includes outlet obstruction, specific bacterial or parasitic infections, cytomegalovirus (CMV) infection, ulcerative colitis (UC) of the pouch, recurrent or misdiagnosed Crohn's disease, anal stenosis, a peripouch abscess, and functional bowel syndromes including irritable pouch syndrome (IPS). (See",
"      <a class=\"local\" href=\"#H1121783413\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients with pouchitis have acute episodes that respond well to a single course of antibiotics. We suggest patients be treated initially with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      at a dose of 1 to 2 g daily (in divided doses) for seven days or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      1 g daily for seven days (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who respond to initial treatment but have relapsing symptoms, we suggest using the probiotic VSL#3 (3 to 6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      or chronic low dose antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=see_link\">",
"       \"Probiotics for gastrointestinal diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who do not respond to initial antibiotic treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      , treatment options include other antibiotic or antibiotic combinations,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      , other antiinflammatory drugs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , or 6-mercaptopurine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Budesonide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Other approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/1\">",
"      Lohmuller JL, Pemberton JH, Dozois RR, et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990; 211:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/2\">",
"      Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003; 124:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/3\">",
"      Mignon M, Stettler C, Phillips SF. Pouchitis--a poorly understood entity. Dis Colon Rectum 1995; 38:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/4\">",
"      Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994; 107:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/5\">",
"      Romanos J, Samarasekera DN, Stebbing JF, et al. Outcome of 200 restorative proctocolectomy operations: the John Radcliffe Hospital experience. Br J Surg 1997; 84:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/6\">",
"      St&aring;hlberg D, Gullberg K, Liljeqvist L, et al. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996; 39:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/7\">",
"      Ker&auml;nen U, Luukkonen P, J&auml;rvinen H. Functional results after restorative proctocolectomy complicated by pouchitis. Dis Colon Rectum 1997; 40:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/8\">",
"      Dozois RR, Goldberg SM, Rothenberger DA, et al. Restorative proctocolectomy with ileal reservoir. Int J Colorectal Dis 1986; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/9\">",
"      Fonkalsrud EW. Endorectal ileoanal anastomosis with isoperistaltic ileal reservoir after colectomy and mucosal proctectomy. Ann Surg 1984; 199:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/10\">",
"      Merrett MN, Mortensen N, Kettlewell M, Jewell DO. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut 1996; 38:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/11\">",
"      de Silva HJ, de Angelis CP, Soper N, et al. Clinical and functional outcome after restorative proctocolectomy. Br J Surg 1991; 78:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/12\">",
"      Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/13\">",
"      Sehgal R, Berg A, Hegarty JP, et al. NOD2/CARD15 mutations correlate with severe pouchitis after ileal pouch-anal anastomosis. Dis Colon Rectum 2010; 53:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/14\">",
"      Nasmyth DG, Johnston D, Godwin PG, et al. Factors influencing bowel function after ileal pouch-anal anastomosis. Br J Surg 1986; 73:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/15\">",
"      Nasmyth DG, Godwin PG, Dixon MF, et al. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology 1989; 96:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/16\">",
"      Sagar PM, Holdsworth PJ, Godwin PG, et al. Comparison of triplicated (S) and quadruplicated (W) pelvic ileal reservoirs. Studies on manovolumetry, fecal bacteriology, fecal volatile fatty acids, mucosal morphology, and functional results. Gastroenterology 1992; 102:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/17\">",
"      Sandborn WJ, Tremaine WJ, Batts KP, et al. Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Dig Dis Sci 1995; 40:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/18\">",
"      de Silva HJ, Jones M, Prince C, et al. Lymphocyte and macrophage subpopulations in pelvic ileal pouches. Gut 1991; 32:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/19\">",
"      Nasmyth DG, Johnston D, Williams NS, et al. Changes in the absorption of bile acids after total colectomy in patients with an ileostomy or pouch-anal anastomosis. Dis Colon Rectum 1989; 32:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/20\">",
"      Santavirta J, Mattila J, Kokki M, et al. Absorption of bile acids after ileoanal anastomosis. Ann Chir Gynaecol 1990; 79:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/21\">",
"      Chaussade S, Denizot Y, Valleur P, et al. Presence of PAF-acether in stool of patients with pouch ileoanal anastomosis and pouchitis. Gastroenterology 1991; 100:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/22\">",
"      Levin KE, Pemberton JH, Phillips SF, et al. Role of oxygen free radicals in the etiology of pouchitis. Dis Colon Rectum 1992; 35:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/23\">",
"      Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001; 49:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/24\">",
"      Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/25\">",
"      de Silva HJ, Millard PR, Soper N, et al. Effects of the faecal stream and stasis on the ileal pouch mucosa. Gut 1991; 32:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/26\">",
"      Goldberg PA, Kamm MA, Nicholls RJ, et al. Contribution of gastrointestinal transit and pouch characteristics in determining pouch function. Gut 1997; 40:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/27\">",
"      Coffey JC, Rowan F, Burke J, et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol 2009; 104:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/28\">",
"      Scarpa M, Grillo A, Faggian D, et al. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. Surgery 2011; 150:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/29\">",
"      McLaughlin SD, Clark SK, Bell AJ, et al. An open study of antibiotics for the treatment of pre-pouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis. Aliment Pharmacol Ther 2009; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/30\">",
"      Shen B, Sanmiguel C, Bennett AE, et al. Irritable pouch syndrome is characterized by visceral hypersensitivity. Inflamm Bowel Dis 2011; 17:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/31\">",
"      Shen B, Achkar JP, Lashner BA, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001; 121:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/32\">",
"      Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004; 126:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/33\">",
"      Casadesus D, Tani T, Wakai T, et al. Possible role of human cytomegalovirus in pouchitis after proctocolectomy with ileal pouch-anal anastomosis in patients with ulcerative colitis. World J Gastroenterol 2007; 13:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/34\">",
"      Mu&ntilde;oz-Juarez M, Pemberton JH, Sandborn WJ, et al. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum 1999; 42:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/35\">",
"      Moonka D, Furth EE, MacDermott RP, Lichtenstein GR. Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol 1998; 93:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/36\">",
"      Shepherd NA, Healey CJ, Warren BF, et al. Distribution of mucosal pathology and an assessment of colonic phenotypic change in the pelvic ileal reservoir. Gut 1993; 34:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/37\">",
"      de Silva HJ, Millard PR, Kettlewell M, et al. Mucosal characteristics of pelvic ileal pouches. Gut 1991; 32:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/38\">",
"      Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. Expert Rev Gastroenterol Hepatol 2009; 3:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/39\">",
"      Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/40\">",
"      Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/41\">",
"      Gosselink MP, Schouten WR, van Lieshout LM, et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004; 47:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/42\">",
"      Isaacs KL, Sandler RS, Abreu M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007; 13:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/43\">",
"      Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008; 8:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/44\">",
"      Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/45\">",
"      Abdelrazeq AS, Kelly SM, Lund JN, Leveson SH. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005; 7:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/46\">",
"      Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002; 16:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/47\">",
"      Tremaine WJ, Sandborn WJ, Wolff BG, et al. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 1997; 11:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/48\">",
"      Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007; 50:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/49\">",
"      McLaughlin SD, Clark SK, Shafi S, et al. Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin Gastroenterol Hepatol 2009; 7:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/50\">",
"      Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007; 25:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/51\">",
"      Belluzzi A, Campieri M, Miglioli M, et al. Evaluation of flogistic pattern in \"pouchitis\" before and after the treatment with budesonide suppositories (abstract). Gastroenterology 1992; 102:A593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/52\">",
"      Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002; 16:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/53\">",
"      Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 2007; 5:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/54\">",
"      Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/55\">",
"      Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/56\">",
"      Miglioli M, Barbara L, Di Febo G, et al. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis. N Engl J Med 1989; 26:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/57\">",
"      Ferrante M, D'Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis 2010; 16:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/58\">",
"      Gadacz TR, McFadden DW, Gabrielson EW, et al. Adenocarcinoma of the ileostomy: the latent risk of cancer after colectomy for ulcerative colitis and familial polyposis. Surgery 1990; 107:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/59\">",
"      Smart PJ, Sastry S, Wells S. Primary mucinous adenocarcinoma developing in an ileostomy stoma. Gut 1988; 29:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/60\">",
"      de Silva HJ, Gatter KC, Millard PR, et al. Crypt cell proliferation and HLA-DR expression in pelvic ileal pouches. J Clin Pathol 1990; 43:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/61\">",
"      Thompson-Fawcett MW, Marcus V, Redston M, et al. Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. Gastroenterology 2001; 121:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/62\">",
"      L&ouml;fberg R, Liljeqvist L, Lindquist K, et al. Dysplasia and DNA aneuploidy in a pelvic pouch. Report of a case. Dis Colon Rectum 1991; 34:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/63\">",
"      Veress B, Reinholt FP, Lindquist K, Liljeqvist L. Different types of mucosal adaptation in the ileal reservoir after restorative proctocolectomy. A two-year follow-up study. APMIS 1990; 98:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32759/abstract/64\">",
"      Shepherd NA. Pouchitis and neoplasia in the pelvic ileal reservoir. Gastroenterology 1995; 109:1381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4073 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32759=[""].join("\n");
var outline_f31_63_32759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Preoperative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Postoperative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1121783413\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1121783420\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1121783427\">",
"      Stool markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Budesonide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURVEILLANCE FOR CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4073\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4073|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/36/7750\" title=\"picture 1\">",
"      Pouchitis Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26647?source=related_link\">",
"      Anti-tumor necrosis factor therapy in ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8279?source=related_link\">",
"      Irritable bowel syndrome in patients with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_63_32760="Rifabutin: Drug information";
var content_f31_63_32760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rifabutin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/32/40452?source=see_link\">",
"    see \"Rifabutin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=see_link\">",
"    see \"Rifabutin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mycobutin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mycobutin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Disseminated MAC in advanced HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis:",
"     </i>",
"     300 mg once daily or 150 mg twice daily to reduce gastrointestinal upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment (unlabeled use; AIDSinfo  guidelines):",
"     </i>",
"     300 mg once daily as an optional add-on to primary therapy of clarithromycin and ethambutol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tuberculosis (unlabeled use as alternative to rifampin; AIDS",
"     </b>",
"     <b>",
"      <i>",
"       info",
"      </i>",
"     </b>",
"     <b>",
"      guidelines):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis of LTBI:",
"     </i>",
"     300 mg once daily for 4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment of active TB:",
"     </i>",
"     300 mg once daily or intermittently 2-3 times weekly as part of multidrug regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concurrent nelfinavir, amprenavir, indinavir:",
"     </b>",
"     Reduce rifabutin dose to 150 mg/day; no change in dose if administered twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concurrent efavirenz (no concomitant protease inhibitor):",
"     </b>",
"     Increase rifabutin dose to 450-600 mg daily, or 600 mg 3 times/week",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F218051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=see_link\">",
"      see \"Rifabutin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis for recurrence of",
"     </b>",
"     <b>",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"     </b>",
"     <b>",
"      complex (MAC) in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral: Infants and Children: 5 mg/kg (maximum dose: 300 mg) once daily as an optional add-on to primary therapy of clarithromycin and ethambutol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis for first episode of MAC in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral: Children &ge;6 years: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of active TB (as alternative to rifampin) in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral: Infants and Children: 10-20 mg/kg (maximum dose: 300 mg) once daily or intermittently 2-3 times weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of severe MAC in HIV-exposed/-infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral: Infants and Children: 10-20 mg/kg (maximum dose: 300 mg) once daily, in addition to primary therapy of clarithromycin and ethambutol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F218036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Reduce dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycobutin&reg;: 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals to minimize nausea or vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of disseminated",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex (MAC) in patients with advanced HIV infection",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F218065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Utilized in multidrug regimens for treatment of MAC; alternative to rifampin as prophylaxis for latent tuberculosis infection (LTBI) or part of multidrug regimen for treatment active tuberculosis infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Rifabutin may be confused with rifampin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (25%), leukopenia (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3%), fever (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 6%), abdominal pain (4%), dyspepsia (3%), eructation (3%), taste perversion (3%), vomiting (3%), flatulence (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (7% to 9%; incidence less than placebo), AST increased (7% to 9%; incidence less than placebo)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aphasia, arthralgia, chest pain, confusion, dyspnea, flu-like syndrome, hepatitis, hemolysis, myositis, parasthesia, seizures, skin discoloration, T-wave abnormalities, uveitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rifabutin, any other rifamycins, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic: May be associated with neutropenia and/or thrombocytopenia (rarely); consider blood monitoring and discontinue permanently if signs of thrombocytopenia (eg, petechial rash).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with liver impairment; discontinue in patients with AST &gt;3 x ULN (symptomatic) or &ge;5 x ULN (regardless of symptoms) or if significant bilirubin and/or alkaline phosphatase elevations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended in severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Must not be administered for MAC prophylaxis to patients with active tuberculosis since its use may lead to the development of TB resistant to both rifabutin and rifampin. Caution that active TB in the HIV-positive patient may present atypically (ie, negative PPD or extrapulmonary manifestations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lenses: Remove soft contact lenses during therapy since permanent staining may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Brown/orange discoloration: Urine, feces, saliva, sweat, tears, and skin may be discolored to brown/orange.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Rifamycin Derivatives may decrease the serum concentration of Alfentanil.  Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Rifamycin Derivatives may increase the metabolism of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Rifamycin Derivatives may increase the metabolism of Angiotensin II Receptor Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Candesartan; Eprosartan; Olmesartan; Telmisartan; Valsartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): Rifamycin Derivatives may increase the metabolism of Antiemetics (5HT3 Antagonists).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dolasetron; Granisetron; Palonosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Rifamycin Derivatives may increase the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Atazanavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Rifamycin Derivatives may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Rifamycin Derivatives may increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Rifamycin Derivatives may increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Rifamycin Derivatives may decrease the serum concentration of BusPIRone.  Management: The degree to which rifampin alters buspirone concentrations warrants the consideration of an alternative to buspirone that is not metabolized by CYP3A4.  If these agents are used together, buspirone dose adjustments may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Rifamycin Derivatives may increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.  Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Rifamycin Derivatives may enhance the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Rifabutin may decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Rifamycin Derivatives may decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Rifamycin Derivatives may increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Rifamycin Derivatives may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Rifamycin Derivatives may increase the metabolism of Dapsone (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Darunavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Darunavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May decrease the metabolism of Rifamycin Derivatives. Rifamycin Derivatives may increase the metabolism of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Rifamycin Derivatives may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Efavirenz. Management: If efavirenz is to be used with daily rifabutin, increase the planned rifabutin adult dose by 50%.  If used with regimens where rifabutin is administered 2-3 times per week, consider doubling the rifabutin dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Rifabutin may decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Rifabutin may decrease the serum concentration of Etravirine.  Management: Avoid concomitant use with rifabutin if a protease inhibitor/ritonavir combination is also used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Rifamycin Derivatives may decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Rifamycin Derivatives. This appears only affect rifabutin. Rifamycin Derivatives may increase the metabolism of Fluconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Fosamprenavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Rifamycin Derivatives may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Rifamycin Derivatives may increase the metabolism of Gefitinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose (within the labeled dosage range) when such a combination is used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Rifamycin Derivatives may decrease the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Rifamycin Derivatives may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Indinavir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Lopinavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Lopinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Rifamycin Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Morphine (Systemic): Rifamycin Derivatives may decrease the serum concentration of Morphine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Rifamycin Derivatives may decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Nelfinavir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Rifabutin. Nevirapine may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Nevirapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Rifamycin Derivatives may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Rifamycin Derivatives may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Rifamycin Derivatives may decrease the serum concentration of Propafenone.  Management: Monitor propafenone serum concentrations closely with rifamycin initiation/dose adjustments/discontinuation. Propafenone serum concentrations/therapeutic effects  may decrease with rifamycins. Propafenone dose adjustments may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.  Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Rifabutin may decrease the serum concentration of Raltegravir. Specifically, minimum serum concentrations (Cmin) may be reduced.  Total raltegravir exposure (i.e., AUC) may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Rifamycin Derivatives may increase the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Rifamycin Derivatives may increase the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Rifamycin Derivatives may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Saquinavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Rifamycin Derivatives may increase the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: Rifamycin Derivatives may increase the metabolism of Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Rifabutin may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as rifampin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase serum concentrations of the active metabolite(s) of Rifabutin. Tipranavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Rifamycin Derivatives may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zaleplon: Rifamycin Derivatives may increase the metabolism of Zaleplon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Rifamycin Derivatives may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F218027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: High-fat meal may decrease the rate but not the extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were seen in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14079709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Mycobutin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $1697.81",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, CBC with differential, platelet count",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alfacid (DE);",
"     </li>",
"     <li>",
"      Ansatipin (ES, FI, SE);",
"     </li>",
"     <li>",
"      Ansatipine (FR);",
"     </li>",
"     <li>",
"      Macbutin (IN);",
"     </li>",
"     <li>",
"      Mycobutin (AR, AT, AU, BE, BG, CH, CZ, DE, GB, GR, HK, HN, HU, IE, IL, IT, KP, LU, NL, NZ, RU, TR, TW);",
"     </li>",
"     <li>",
"      Ributin (IN);",
"     </li>",
"     <li>",
"      Rifabutin &rdquo;Pharmacia&rdquo; (DK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-dependent RNA polymerase at the beta subunit which prevents chain initiation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily, 53%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 9.32 L/kg; distributes to body tissues including the lungs, liver, spleen, eyes, and kidneys",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To 5 metabolites; predominantly 25-O-desacetyl-rifabutin (antimicrobial activity equivalent to parent drug; serum AUC 10% of parent drug) and 31-hydroxy-rifabutin (serum AUC 7% of parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: HIV: 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 45 hours (range: 16-69 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (53% as metabolites); feces (30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agins BD, Berman DS, Spicehandler D, et al, &ldquo;Effect of Combined Therapy with Ansamycin, Clofazimine, Ethambutol, and Isoniazid for",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Infection in Patients With AIDS,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1989, 159(4):784-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/2926169/pubmed\" id=\"2926169\" target=\"_blank\">",
"        2926169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\" September 14, 2011, 1-207.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for AIDS and Associated Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(904):79-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/8394503/pubmed\" id=\"8394503\" target=\"_blank\">",
"        8394503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunn AM, Tizer K, Cervia JS, et al, &ldquo;Rifabutin-Associated Uveitis in a Pediatric Patient,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):246-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/7761197/pubmed\" id=\"7761197\" target=\"_blank\">",
"        7761197",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection,&rdquo; January 29, 2008. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Havlir D, Torriani F, and Dube M, &ldquo;Uveitis Associated With Rifabutin Prophylaxis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 121(7):510-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/8067648/pubmed\" id=\"8067648\" target=\"_blank\">",
"        8067648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoy J, Mijch A, Sandland M, et al, &ldquo;Quadruple-Drug Therapy for",
"      <i>",
"       Mycobacterium avium-intracellulare",
"      </i>",
"      Bacteremia in AIDS Patients,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1990, 161(4):801-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/2156947/pubmed\" id=\"2156947\" target=\"_blank\">",
"        2156947",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobs DS, Piliero PJ, Kuperwaser MG, et al, &ldquo;Acute Uveitis Associated With Rifabutin Use in Patients With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 1994, 118(6):716-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/7977598/pubmed\" id=\"7977598\" target=\"_blank\">",
"        7977598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karbassi M, and Nikou S, &ldquo;Acute Uveitis in Patients With Acquired Immunodeficiency Syndrome Receiving Prophylactic Rifabutin,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1995, 113(6):699-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/7786200/pubmed\" id=\"7786200\" target=\"_blank\">",
"        7786200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelleher P, Helbert M, Anderson J, et al, &ldquo;Uveitis: Incidence Study,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1994, 8(Suppl 4):18, abstract.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krause PJ, Hight DW, Schwartz AN, et al, &ldquo;Successful Management of",
"      <i>",
"       Mycobacterium intracellulare",
"      </i>",
"      Pneumonia in a Child,&rdquo;",
"      <i>",
"       Pediatr Infect Dis",
"      </i>",
"      , 1986, 5(2):269-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/3952014/pubmed\" id=\"3952014\" target=\"_blank\">",
"        3952014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levin RH and Bolinger AM, &ldquo;Treatment of Nontuberculous Mycobacterial Infections in Pediatric Patients,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(7):545-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/2843317/pubmed\" id=\"2843317\" target=\"_blank\">",
"        2843317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris JT and Kelly JW, &ldquo;Rifabutin-Induced Ageusia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1993, 119(2):171-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nightingale SD, Cameron DW, Gordin FM, et al, &ldquo;Two Controlled Trials of Rifabutin Prophylaxis Against",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Infection in AIDS,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(12):828-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/8179648/pubmed\" id=\"8179648\" target=\"_blank\">",
"        8179648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Public Health Service Task Force on Prophylaxis and Therapy for",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex, &ldquo;Recommendations on Prophylaxis and Therapy for Disseminated",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Disease in Patients Infected With the Human Immunodeficiency Virus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(12):898-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/8395019/pubmed\" id=\"8395019\" target=\"_blank\">",
"        8395019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rifai A, Peyman GA, Daun M, et al, &ldquo;Rifabutin Associated Uveitis During Prophylaxis for",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Infection,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1995, 113(6):707.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tseng AL and Walmsley SL, &ldquo;Rifabutin-Associated Uveitis,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(11):1149-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/63/32760/abstract-text/8573961/pubmed\" id=\"8573961\" target=\"_blank\">",
"        8573961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9863 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32760=[""].join("\n");
var outline_f31_63_32760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218030\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218031\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218069\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218034\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218051\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218035\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218036\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218010\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803201\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218011\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218065\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218067\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218015\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218000\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218062\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218005\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218027\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218006\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079708\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218040\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079709\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218018\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218017\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218008\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038798\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217999\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218014\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9863\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9863|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/32/40452?source=related_link\">",
"      Rifabutin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=related_link\">",
"      Rifabutin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_63_32761="Adult attention deficit hyperactivity disorder";
var content_f31_63_32761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adult attention deficit hyperactivity disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32761/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32761/contributors\">",
"     H Russell Searight, PhD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32761/contributors\">",
"     John M Burke, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32761/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32761/contributors\">",
"     David Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32761/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/63/32761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD) was originally believed to be primarily a pediatric condition. However, the available data suggest that between 30 and 70 percent of children with ADHD continue to manifest symptoms in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It is estimated that between 1 and 7 percent of the adult population experiences ADHD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulants, tricyclic antidepressants, and bupropion are the most commonly used medications in adults with ADHD, but response rates may be lower in adults compared to children. Cognitive behavioral therapy (CBT) has been show to be efficacious in conjunction with medication.",
"   </p>",
"   <p>",
"    This topic addresses ADHD in adults. ADHD in children is addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4954?source=see_link\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of adult ADHD based on DSM-IV criteria was estimated to be 2.5 percent in a meta-analysis of five regional studies involving several countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/6\">",
"     6",
"    </a>",
"    ]. A representative, nationwide study in the US found an adult prevalence of 4.4 percent using conservative diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADHD in adults has been found to be more common in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/7\">",
"     7",
"    </a>",
"    ]. The prevalence of ADHD appears to decrease with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies and clinical response to drugs with noradrenergic activity suggest that the pathophysiologic basis of ADHD centers on an imbalance in catecholamine metabolism in the cerebral cortex.",
"   </p>",
"   <p>",
"    The noradrenergic system modulates higher cortical functions including attention, alertness, vigilance, and executive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/8\">",
"     8",
"    </a>",
"    ]. Rat models suggest that an imbalance between the norepinephrine and dopamine systems in the prefrontal cortex contribute to the pathogenesis of ADHD, with inhibitory dopaminergic activity decreased and norepinephrine activity increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human studies have found an increase in dopamine transporter density (which may clear dopamine from the synapse too quickly) in patients with ADHD compared with healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    (a stimulant used to treat ADHD) increases extracellular dopamine in the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic studies also suggest that adrenergic and possibly serotonergic genes play a role in the development of ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Several candidate genes, including the D2 and D4 dopamine genes, have been studied. The dopamine D4 receptor (DRD4) gene has been associated with performance on tasks assessing attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/16\">",
"     16",
"    </a>",
"    ], short-term memory, and executive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/17\">",
"     17",
"    </a>",
"    ], but it has not been consistently correlated with a formal ADHD diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;DSM-IV criteria for ADHD emphasize both inattention and",
"    <span class=\"nowrap\">",
"     hyperactivity/impulsivity",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"mobipreview.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ). These criteria best describe pediatric presentations; symptoms are more subtle in adults. Poor concentration, distractibility, elevated motor activity, and impulsivity should be pervasive features disrupting at least two domains of daily life (eg, school, family, peer relationships).",
"   </p>",
"   <p>",
"    While the precise time of symptom onset is often difficult to determine, the requirement of DSM-IV that symptoms be established by age seven is increasingly being called into question [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/18\">",
"     18",
"    </a>",
"    ]. Studies have suggested that the age be increased to 12 years, or be left unspecified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A study comparing adults who met all DSM-IV criteria for ADHD with those who met all criteria except for later age at symptom onset (in whom 83 percent had symptoms by age 12) found no difference in psychiatric comorbidity, functional impairment, or familial transmission between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/19\">",
"     19",
"    </a>",
"    ]. Additionally, levels and patterns of substance abuse are similar for patients with early and late onset of ADHD symptoms, and exceed substance use in adults with subthreshold symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a growing consensus that the central feature of ADHD is disinhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/22\">",
"     22",
"    </a>",
"    ]. This typically manifests as poor self-regulation, inability to prevent immediate responding, and difficulty with both focused attention and goal-directed thought and action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Hyperactivity is less overt in adults. The \"on the go\" drivenness seen in children is replaced with restlessness, difficulty relaxing, and feeling chronically \"on edge.\" Deficits in sustained attention and concentration may become more apparent in late adolescence and early adulthood as responsibilities increase. Appointments, social commitments, and school and work deadlines are frequently forgotten. Completed work is frequently misplaced amid clutter.",
"   </p>",
"   <p>",
"    Because of difficulties with breaking down tasks into subparts, as well as a pattern of immediate reaction to environmental demands, adults with ADHD often appear hectic and disorganized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/25\">",
"     25",
"    </a>",
"    ]. Prioritizing is a common problem; important tasks are not completed while trivial distractions receive inordinate time. Impulsivity often takes the form of socially inappropriate behavior (eg, blurting out thoughts that are rude or insulting). Many of the symptoms are reported by others in the patient's life, and affected adults themselves express frustration over their chronic inability to be organized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/1\">",
"     1",
"    </a>",
"    ]. A subset of adults with ADHD have difficulties with executive functioning (sustained attention, working memory, verbal fluency, and speed of motor and mental processing), identified by psychometric testing; this subset had greater functional impairment in one study, resulting in lower academic, occupational, and socioeconomic achievement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Utah criteria were developed in an attempt to reflect the distinct features of ADHD that occur in adults (",
"    <a class=\"graphic graphic_table graphicRef70999 \" href=\"mobipreview.htm?11/7/11387\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/2\">",
"     2",
"    </a>",
"    ]. A persistent history of inattention and hyperactivity dating back to childhood may be demonstrated in one of three ways: a childhood history meeting DSM-IV criteria for ADHD; a clear history of impulsivity, school behavior problems, over-excitability, or temper outbursts; or retrospective ratings of ADHD symptoms on the Wender Utah Rating Scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/27\">",
"     27",
"    </a>",
"    ]. Hyperactivity and inattention should be present along with two of five other symptoms. In contrast with DSM-IV, the Utah system emphasizes emotional symptoms, such as sudden angry outbursts, and intense affective lability.",
"   </p>",
"   <p>",
"    It is estimated that 30 to 70 percent of ADHD adults have a comorbid learning disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/25\">",
"     25",
"    </a>",
"    ]. For those adults pursuing high school equivalency, undergraduate or graduate studies, appropriate and reasonable educational accommodations are supported by federal law. Clear documentation of the diagnoses will be necessary for these accommodations to be provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic evaluation should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A developmental history, with an attempt to corroborate the information with other sources. Symptoms should be consistently present since early childhood.",
"     </li>",
"     <li>",
"      Assessment of the impact of core ADHD symptoms on current occupational, school, and relationship functioning.",
"     </li>",
"     <li>",
"      Assessment of attention, concentration, distractibility, and short-term memory.",
"     </li>",
"     <li>",
"      Assessment for the presence of other psychiatric disorders and substance abuse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have equivocal results after the above evaluation should be referred for psychologic evaluation.",
"   </p>",
"   <p>",
"    In addition to assessing current ADHD symptoms and their duration, information about academic grades, conduct in school, and psychiatric history should be obtained. Patients should be encouraged to provide past school records and information from their parents.",
"   </p>",
"   <p>",
"    There is debate about whether adults can provide reliable information regarding current or past ADHD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/2,28-31\">",
"     2,28-31",
"    </a>",
"    ]. Accuracy of symptom reporting is variable depending on the setting (psychiatric versus primary care), whether reports are retrospective or current, and who is reporting (patient or family member). Adults may retrospectively report more childhood symptoms than their parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/32\">",
"     32",
"    </a>",
"    ], while 20 percent of adults with documented childhood ADHD do not recall this history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a nonclinical sample, adults' current self-rated symptoms strongly correlated with ratings from parents and current partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/28\">",
"     28",
"    </a>",
"    ]. Symptom reporting may be more reliable when behaviorally specific ratings rather than open-ended questions are employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/25\">",
"     25",
"    </a>",
"    ]. Typically, past disruptive hyperactive symptoms are reliably reported but adults tended to underreport inattention and other cognitive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory testing, including thyroid function studies, is undertaken to identify medical conditions that may present with symptoms similar to those of ADHD (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rating scales",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four most commonly used self-report measures for ADHD are the Wender rating scale, the Copeland symptom checklist, the Conners adult ADHD scale, and the Brown scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/30,37-39\">",
"     30,37-39",
"    </a>",
"    ]. There are a growing number of brief self-administered screens, including the WHO Adult Self-Report-Scale-V1.1 screener (ASRS-v1.1) (",
"    <a class=\"graphic graphic_form graphicRef60498 \" href=\"mobipreview.htm?22/39/23154\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/40\">",
"     40",
"    </a>",
"    ]. These screening tools should not be used for diagnostic purposes. Inattention, impulsivity, and volatile moods are features of several other psychiatric conditions. The 25-item Wender Utah Rating Scale, when used alone, misclassifies about 40 percent of non-ADHD adults as having the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychiatric conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many psychiatric syndromes are associated with impairment in attention, concentration, disinhibition of inappropriate behavior, and difficulty with task completion. The requirement that ADHD symptoms must have persisted since age seven can be useful in distinguishing ADHD from other psychiatric conditions such as depression, substance abuse, and most anxiety disorders. While these conditions may be chronic in adults, they typically develop in adolescence or adulthood rather than in early childhood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression often includes attention and concentration difficulties, as well as irritable mood. An enduring dysphoric mood or anhedonia, and sleep and appetite disturbance are suggestive of depression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bipolar I disorder includes mania which is typically very distinctive with press-of-speech, delusions, and socially reckless behavior. Bipolar II features include depression alternating with less severe, hypomania, and may be misdiagnosed as ADHD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"       \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"      </a>",
"      .) Most adults with ADHD do not have coexisting bipolar disorder, but childhood ADHD is a risk factor for early onset bipolar illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with generalized anxiety disorder (GAD) may emphasize concentration problems. GAD can be distinguished by the presence of chronic, excessive worry, apprehension about the future, and autonomic over-arousal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"       \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long term marijuana or alcohol abusers may report inattention and poor concentration. Substance abuse often coexists with ADHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/1,2,43\">",
"       1,2,43",
"      </a>",
"      ]. It is difficult to accurately diagnose ADHD with ongoing substance abuse. Patients should abstain from drug use for at least a two- to three-month period and cognitive functions then reassessed.",
"     </li>",
"     <li>",
"      Antisocial personality disorder, characterized by arrests, repeated failure to fulfill parental or work-related obligations, and an absence of remorse, may be confused with ADHD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40824?source=see_link\">",
"       \"Personality disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these syndromes also coexist with adult ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In one study of 56 adults who met the DSM-III-R criteria for ADHD, the majority (87 percent) had additional psychiatric diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/44\">",
"     44",
"    </a>",
"    ]. Additional diagnoses included generalized anxiety disorder, alcohol abuse, drug abuse, dysthymic disorder, and cyclothymic disorder.",
"   </p>",
"   <p>",
"    Antisocial personality features may be found in up to 20 percent of adults with ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/46\">",
"     46",
"    </a>",
"    ]. Clinicians should be cautious about prescribing stimulants to these patients.",
"   </p>",
"   <p>",
"    Comorbid learning disabilities from childhood often will continue to be evident in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/46\">",
"     46",
"    </a>",
"    ]. A learning disability is defined as significantly poorer performance on a standardized academic test (eg, reading, spelling, mathematics) than would be expected given the patient's age, IQ, and educational background [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=see_link\">",
"     \"Specific learning disabilities in children: Clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical conditions that may mimic adult ADHD include hyperthyroidism, petit mal and partial complex seizures, hearing deficits, lead toxicity, sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], and medication interactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    .) Patients with histories of head injuries may exhibit problems with attention, concentration, and memory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bulk of the available data on the treatment of ADHD are derived from studies in children, limiting the ability to make evidence-based recommendations for adults. Nonetheless, the use of medications to treat ADHD in adults has increased markedly in the United States (by 90 percent from 2002 to 2005), with adults receiving one third of all prescriptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/50\">",
"     50",
"    </a>",
"    ]. This pattern is not seen in other countries.",
"   </p>",
"   <p>",
"    The mainstay of ADHD treatment is pharmacotherapy. Counseling and specific psychotherapies may be required to assist patients in restructuring dysfunctional life patterns while pharmacotherapy improves their ability to focus and organize their lives.",
"   </p>",
"   <p>",
"    Based upon the pathophysiologic mechanisms cited above, medications acting through the norepinephrine pathways of the CNS appear to most directly treat ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Stimulants are a major component of pharmacologic therapy in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. For adults, stimulants and antidepressants (particularly those with norepinephrine activity) primarily have been used to treat ADHD. Doses for these medications are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef50379 \" href=\"mobipreview.htm?22/32/23054\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulants are the most commonly used medications in adults with ADHD. However, the addicting nature of stimulants, the chronicity of ADHD, and the large number of potentially comorbid conditions in adults have led some experts to recommend a trial of a nonstimulant agent first. Nevertheless, for the patient with no contraindications, long-term stimulant use is a reasonable choice for pharmacologic therapy.",
"   </p>",
"   <p>",
"    These agents stimulate the release of catecholamines from storage sites at CNS synapses; the exact focus of the pharmacologic effect is unclear. Increased norepinephrine and dopamine concentrations in the brainstem, midbrain, and frontal cortex have been postulated.",
"   </p>",
"   <p>",
"    The cognitive functions influenced by stimulants impact a number of daily living skills. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ingestion has been found to reduce driving errors in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/55\">",
"     55",
"    </a>",
"    ]. Stimulants may also produce these effects in patients without ADHD, and not all patients with ADHD improve with such therapy. Thus, the patient's response cannot be used to confirm or exclude the diagnosis of ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulants are less effective in adults than in children with ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/57\">",
"     57",
"    </a>",
"    ]. Response rates in adults vary from 25 to 78 percent in the limited number of studies available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/58\">",
"     58",
"    </a>",
"    ]. This wide range reflects variability in diagnostic criteria, definitions of a positive response, drug dosing, and significant comorbidity among studied patients. Higher doses of stimulant medications are more effective than lower doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]; the highest response rate (78 percent) was achieved in a study that used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Stimulant preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of stimulant preparations are available, and differ in their pharmacokinetics, but have similar efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/62\">",
"     62",
"    </a>",
"    ]. Most contain racemic mixtures of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/52,61,63\">",
"     52,61,63",
"    </a>",
"    ], and are either short-acting (immediate release) or long-duration, formulated in wax matrix, beads, or osmotic-release preparations. A patch is also available. Because of delayed action, the methylphenidate patch should be applied two hours before its effect is needed.",
"   </p>",
"   <p>",
"    Other stimulants are amphetamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/64\">",
"     64",
"    </a>",
"    ]: dextroamphetamine; a racemic mixture of d- and l-amphetamine (Adderall XR); and a prodrug of dextroamphetamine, lisdexamfetamine (Vyvanse) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/65\">",
"     65",
"    </a>",
"    ]. As a prodrug, lisdexamfetamine may have lower abuse potential (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Abuse potential'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cardiovascular side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular effects of stimulants are of potentially greater concern in adults than in children. Stimulants increase heart rate and blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In a randomized study, blood pressure increase with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    averaged 5 mm Hg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/68\">",
"     68",
"    </a>",
"    ]. In response to reports of sudden death with use of stimulants in both adults and children treated for ADHD, the FDA has required that a patient medication guide be provided with dispensing of stimulants used for treatment of ADHD, describing cardiovascular risks (hypertension, cardiac arrest, arrhythmias, and stroke) and risks of adverse psychiatric symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/69\">",
"     69",
"    </a>",
"    ]. Blood pressure and heart rate should be closely monitored when initiating treatment with stimulants in adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common initial side effect is sleep disturbance, characterized by delayed onset of sleep. This is also a common complaint of adults with untreated ADHD. Thus, it may be helpful to assess the patient's sleep patterns for several weeks if sleep problems develop after initiation of therapy, before altering the dosage or the timing of administration.",
"   </p>",
"   <p>",
"    Another side effect of stimulants may be a decrease in appetite resulting in weight loss. Stimulants can also cause the emergence of tics, which may be permanent in patients with a genetic or personal history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Abuse potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caution should be exercised both in making the diagnosis of ADHD and in avoiding the use of stimulants in patients with a history of substance abuse. For the patient with a history of substance abuse, a tricyclic antidepressant (TCA) that has activity through norepinephrine pathways (eg, desipramine or nortriptyline), or atomoxetine might be a preferred agent (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Antidepressants'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Atomoxetine'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The increase in extracellular dopamine that occurs with consumption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    is similar to the increase seen with use of cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/11,71\">",
"     11,71",
"    </a>",
"    ]. Oral methylphenidate does not cause a \"high\" because of the slow delivery to the brain when taken orally. However, injecting liquid methylphenidate can cause a high similar to that of cocaine.",
"   </p>",
"   <p>",
"    Adult patients may require larger dosages of stimulants than those prescribed to children. Thus, it is important to document the patient's symptoms and the response during dosage titration. Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and dextroamphetamine are C-II controlled substances, most states limit prescriptions to a 30-day supply and do not authorize refills. However, for chronic conditions such as ADHD, a 90-day supply may be authorized if the dosage regimen is stable. This requires frequent contact between the patient and clinician for reevaluation.",
"   </p>",
"   <p>",
"    The prodrug lisdexafetamine, which received US Federal Drug Administration approval for use in adults in 2008, may have lower abuse potential. A comparison of 100 mg lisdexamfetamine and 40 mg immediate release d-amphetamine in subjects with a history of drug abuse found that subjective \"liking\" responses were significantly less for lisdexamfetamine; there was no difference, however, between 150 mg lisdexamfetamine and 40 mg immediate release d-amphetamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants that inhibit reuptake of norepinephrine, and thereby increase the concentration of catecholamines in the CNS, have been evaluated for the treatment of ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tricyclic antidepressants (TCAs) inhibit the reuptake of norepinephrine and serotonin. The one available controlled trial of TCAs investigated the use of desipramine (target dose 200 mg per day) in 41 adults with ADHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/51\">",
"       51",
"      </a>",
"      ]. A response rate of 68 percent was noted in the desipramine group, compared to no response with placebo. The secondary amine TCAs, such as desipramine and nortriptyline, may be preferred because of greater effects on norepinephrine than on serotonin and a better side effect profile than other TCAs. Because of the possibility of cardiac conduction abnormalities, an electrocardiogram should be obtained before initiating TCA therapy and after the dosage is stabilized.",
"     </li>",
"     <li>",
"      The response to selective serotonin reuptake inhibitors (SSRIs) has been less promising than TCAs in adults with ADHD, but the data are limited [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/52,73\">",
"       52,73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bupropion, an atypical antidepressant with more stimulant properties than the TCAs, may be effective in adults with ADHD. Bupropion is a reasonable alternative treatment for patients with cardiac or other medical contraindications to stimulants or TCAs. Response rates to bupropion, in a range from 200 to 450 mg daily, varied between 53 and 76 percent in two studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. A positive effect on ADHD symptoms can be seen at two weeks after initiation of therapy.",
"     </li>",
"     <li>",
"      Therapy with monoamine oxidase (MAO) inhibitors has produced variable responses in patients with ADHD, but may be tried in patients who have responded poorly to other therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antidepressant therapy in adults with ADHD may be particularly helpful in reducing affective instability and controlling a coexistent mood disturbance. Because of the different effects of stimulants and antidepressants, some patients may benefit from the combination of a stimulant and an antidepressant.",
"   </p>",
"   <p>",
"    Adverse effects of antidepressants often limit the ability to titrate the dose to an effective level. Drowsiness is common but may be minimized by taking the antidepressant at bedtime and slowly titrating to the target dosage. Anticholinergic effects such as dry mouth, constipation, and urinary retention may be troublesome, as are weight gain and postural hypotension. Sexual dysfunction is more common with the agents that affect serotonin reuptake than with secondary amine TCAs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If sedation is problematic, bupropion may be an alternative agent. The use of bupropion is contraindicated in patients with a history of seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Atomoxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor approved by the United States Food and Drug Administration (US FDA) for the treatment of ADHD in children older than 6 years, adolescents, and adults. It is the only FDA approved medication for the treatment of ADHD that is not controlled under the Controlled Substance Act and the first ADHD pharmacotherapy approved for use in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/76\">",
"     76",
"    </a>",
"    ]. A warning was issued by the FDA in 2005 that atomoxetine has been associated with an increased risk of suicide in children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atomoxetine is an oral capsule (5,10,18,25,40, and 60 mg) and can be taken once or twice per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/76\">",
"     76",
"    </a>",
"    ]. Approval in adults was based on two ten week trials that tested atomoxetine in total daily doses of 60 to 120",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (mean 95",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    in which ADHD symptoms were significantly improved compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/78\">",
"     78",
"    </a>",
"    ]. It is recommended that adults be started at a dose of 40 mg for a minimum of three days, and then increased to 80 mg; the dose may be increased to a maximum of 100 mg after two to four weeks. Alternatively, some recommend starting at 25 mg for one week, increasing to 50 mg for week two and then titrating upwards.",
"   </p>",
"   <p>",
"    Adverse effects include (but are not limited to) weight loss, abdominal pain, decreased appetite, vomiting, nausea, dyspepsia, and sleep disturbance. In addition, based on reports of severe liver injury in two patients (a teenager and an adult) who were being treated with atomoxetine for several months, the US FDA added a warning that atomoxetine should be discontinued in patients who develop jaundice or laboratory evidence of liver injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympatholytics have been used in the management of ADHD. Clonidine is a centrally acting alpha-2 agonist that decreases sympathetic outflow from the CNS. While this agent may be beneficial in children and adolescents, particularly those with significant hyperactivity and aggressive behavior, the benefits in adults are less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/80\">",
"     80",
"    </a>",
"    ]. Sedation is the most common adverse effect of clonidine. The antihypertensive effects of clonidine may be beneficial in a patient with hypertension but may limit its usefulness in other patients.",
"   </p>",
"   <p>",
"    A number of complementary and alternative medicine therapies have been tried in patients with ADHD. The efficacy is uncertain; further research is required before any can be recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Choice of pharmacotherapy agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulants are a major component of pharmacologic therapy in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The bulk of the data in adults supports the efficacy of stimulants. However, the addicting nature of stimulants, the chronicity of ADHD, and the large number of potentially comorbid conditions in adults have led some experts to recommend a trial of a nonstimulant agent first.",
"   </p>",
"   <p>",
"    Nevertheless, for the patient with no contraindications, long-term stimulant use is a reasonable choice for pharmacologic therapy. The efficacy of all of the stimulants appears to be similar, although the greatest experience is with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    . For the patient with a history of substance abuse, a tricyclic antidepressant (TCA) that has activity through norepinephrine pathways (eg, desipramine or nortriptyline), or atomoxetine might be a preferred agent. For the patient with cardiac or other medical contraindications to stimulants or TCAs, bupropion is a reasonable alternative.",
"   </p>",
"   <p>",
"    There are limited data comparing the stimulants to antidepressants, but the available research suggests that they are similarly effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/82\">",
"     82",
"    </a>",
"    ]. A reasonable approach is to start with an agent of one class and switch to an agent from another class if the patient fails to respond or has significant side effects. As mentioned, combinations of these drugs can also be used.",
"   </p>",
"   <p>",
"    For patients with mood, anxiety,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substance abuse conditions who also have features of ADHD, the primary condition should be initially treated and ADHD symptoms addressed if they persist after remission of the primary condition. Conversely, ADHD should be considered when patients fail to respond to pharmacotherapy for a mood or anxiety disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adult ADHD is viewed as a chronic, life-long condition continuing from early childhood. Thus, continued pharmacotherapy throughout adulthood is usually indicated. A meta-analysis of six studies following children with ADHD into adolescence or young adulthood found that children who did not receive medication (stimulant therapy) had twice the risk of subsequent substance abuse compared with those who did receive medication (OR 1.9, 95% CI 1.1-3.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/83\">",
"     83",
"    </a>",
"    ]. Two subsequent prospective studies, in contrast, concluded that stimulant treatment did not impact risk for adult substance abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/84,85\">",
"     84,85",
"    </a>",
"    ] and one found that early rather than later initiation of stimulant therapy in childhood was associated with lower levels of adult substance abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials suggest that cognitive behavioral therapies are helpful in the treatment of adult ADHD. Other types of psychotherapy have been used to address focal areas of functional impairment",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized trials have found cognitive-behavioral therapy (CBT) in combination with pharmacotherapy to reduce ADHD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. Two small trials compared the combination of medication and CBT to medication alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The third trial, of 86 adults with ADHD already on medication, found that the addition of CBT resulted in a greater reduction of ADHD symptoms than an intervention that combined relaxation and educational support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/89\">",
"     89",
"    </a>",
"    ]. Improvement observed following the 15-week CBT intervention was maintained at 6 and 12-month assessments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Meta-cognitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-cognitive therapy (MCT), a group-administered, protocol driven psychotherapy for adults with ADHD, has shown efficacy in a single, randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/90\">",
"     90",
"    </a>",
"    ]. MCT incorporates cognitive-behavioral principles and training in executive self-management skills. In a 12-week randomized trial of 88 adults with ADHD, MCT led to greater improvement in ADHD symptoms than a supportive group therapy. The efficacy of MCT was independent of whether the patient was receiving medication for ADHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other psychotherapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual psychotherapy is often used to treat the low self esteem that often accompanies the disorder or specific areas of functional impairment, such as academic or occupational failure. Marital therapy can be used to increase partners' skills in communication, conflict resolution, and problem solving, as well as provide education to the patient's spouse about ADHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Instruction in time management and organizational skills, independent from MCT, can be helpful. Planning and organization can be improved by encouraging regular list making or use of a computerized schedule. Tasks to reduce distractions may include having a clutter free desktop, a carrel style desk, or a windowless office. Task completion can be improved by systemically breaking down large projects into manageable \"chunks,\" each with its own deadline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32761/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with ADHD should be educated about their elevated risk for drug and alcohol dependence and encouraged to drink in moderation or abstain. &nbsp;Substance use should be monitored over the course of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 30 and 70 percent of children with ADHD have continued symptoms into adulthood. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DSM-IV criteria for ADHD (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"mobipreview.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      ) requires a history that ADHD symptoms were present by age seven, though it has been suggested this be extended to age twelve. Hyperactivity is less overt in adults than children; adults more often appear hectic and disorganized. Utah criteria were developed to identify ADHD in adults (",
"      <a class=\"graphic graphic_table graphicRef70999 \" href=\"mobipreview.htm?11/7/11387\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features and diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no gold standard diagnostic test for ADHD in adults. Diagnosis is based on the clinical interview; assessment of mental status, memory, and cognitive testing with distraction; and medical evaluation including neurologic examination and thyroid function studies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for ADHD includes depression, bipolar disorder, generalized anxiety, substance abuse, and learning disability; some of these may be comorbid diagnoses. Medical conditions with symptoms overlapping ADHD include hyperthyroidism, seizure disorder, lead toxicity, and adverse effects from medications or head injury. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stimulants are the most commonly used medications in adults with ADHD, but response rates may be lower than in children. Stimulants differ in pharmacokinetics but have similar efficacy. Blood pressure and heart rate should be closely monitored when initiating stimulant treatment in adults. Stimulants should be avoided in patients with history of or increased risk for substance abuse. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Stimulants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary amine tricyclic antidepressants (TCAs) with activity through norepinephrine pathways (eg desipramine and nortriptyline) and bupropion have been effective as monotherapy for ADHD, or in combination with stimulants. An electrocardiogram should be obtained before initiating TCA therapy, and after achieving target dose. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atomoxetine is the only approved medication for the treatment of ADHD that is not controlled under the Controlled Substance Act in the US. There are case reports of severe liver injury, and other adverse effects include gastrointestinal symptoms and sleep disturbance. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Atomoxetine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adult ADHD is a chronic, life-long condition with onset in childhood; continued pharmacotherapy throughout adulthood is usually indicated. For the patient with no contraindications, long-term stimulant use is a reasonable choice. For the patient with a history of substance abuse, a tricyclic antidepressant or atomoxetine is preferred. Bupropion is a reasonable alternative for the patient with cardiac or other medical contraindications to stimulants or TCAs. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Choice of pharmacotherapy agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cognitive behavioral therapy and skills training may be helpful adjuncts to pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/1\">",
"      Vollmer, S. AD/HD: it's not just in children. Family Practice Recertification 1998; 20:45.",
"     </a>",
"    </li>",
"    <li>",
"     Wender, PH. Attention-Deficit Hyperactivity Disorder in Adults, Oxford University Press, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/3\">",
"      Cantwell DP. Hyperactive children have grown up. What have we learned about what happens to them? Arch Gen Psychiatry 1985; 42:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/4\">",
"      Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 1991; 48:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/5\">",
"      Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/6\">",
"      Simon V, Czobor P, B&aacute;lint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009; 194:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/7\">",
"      Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/8\">",
"      Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/9\">",
"      Russell V, Allie S, Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder--the spontaneously hypertensive rat. Behav Brain Res 2000; 117:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/10\">",
"      Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/11\">",
"      Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21:RC121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/12\">",
"      Collaborative possibilities for molecular genetic studies of attention deficit hyperactivity disorder: report from an international conference. The ADHD Molecular Genetics Network. Am J Med Genet 2000; 96:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/13\">",
"      Faraone SV, Doyle AE, Mick E, Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/14\">",
"      Comings DE, Gade-Andavolu R, Gonzalez N, et al. Comparison of the role of dopamine, serotonin, and noradrenaline genes in ADHD, ODD and conduct disorder: multivariate regression analysis of 20 genes. Clin Genet 2000; 57:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/15\">",
"      Thapar A, Holmes J, Poulton K, Harrington R. Genetic basis of attention deficit and hyperactivity. Br J Psychiatry 1999; 174:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/16\">",
"      Manor I, Tyano S, Eisenberg J, et al. The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). Mol Psychiatry 2002; 7:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/17\">",
"      Seidman LJ, Biederman J, Weber W, et al. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/18\">",
"      Alpert JE, Maddocks A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996; 62:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/19\">",
"      Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry 2006; 163:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/20\">",
"      McGough JJ, McCracken JT. Adult attention deficit hyperactivity disorder: moving beyond DSM-IV. Am J Psychiatry 2006; 163:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/21\">",
"      Faraone SV, Wilens TE, Petty C, et al. Substance use among ADHD adults: implications of late onset and subthreshold diagnoses. Am J Addict 2007; 16 Suppl 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     Barkley, RA. AD/HD and the Nature of Self-Control, Guilford, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/23\">",
"      Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/24\">",
"      Ossmann JM, Mulligan NW. Inhibition and attention deficit hyperactivity disorder in adults. Am J Psychol 2003; 116:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/25\">",
"      Silver, LB. Attention-deficit/hyperactivity disorder in adult life. Child Adoles Psychiatr Clin North Am 2000; 9:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/26\">",
"      Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 2006; 163:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/27\">",
"      Donnelly CL. History and pathophysiology of ADHD. CNS Spectr 2006; 11:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/28\">",
"      Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry 2000; 157:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/29\">",
"      Shaffer D. Attention deficit hyperactivity disorder in adults. Am J Psychiatry 1994; 151:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/30\">",
"      Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/31\">",
"      Mannuzza S, Klein RG, Klein DF, et al. Accuracy of adult recall of childhood attention deficit hyperactivity disorder. Am J Psychiatry 2002; 159:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/32\">",
"      Zucker M, Morris MK, Ingram SM, et al. Concordance of self- and informant ratings of adults' current and childhood attention-deficit/hyperactivity disorder symptoms. Psychol Assess 2002; 14:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/33\">",
"      Young, S. The YAQ-S and YAQ-1: The development of self and informant questionnaires reporting on current adult ADHD symptomatology, comorbid and associated problems. Personality and Individual Differences 2004; 36:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/34\">",
"      Sandra Kooij JJ, Marije Boonstra A, Swinkels SH, et al. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord 2008; 11:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/35\">",
"      Fargason RE, Ford CV. Attention deficit hyperactivity disorder in adults: diagnosis, treatment, and prognosis. South Med J 1994; 87:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/36\">",
"      Nahlik, JE, Searight, HR. Diagnosis and treatment of attention deficit hyperactivity disorder. Primary Care Reports 1996; 2:65.",
"     </a>",
"    </li>",
"    <li>",
"     Brown, TE. Brown Attention Deficit Disorders Scales Manual. San Antonio, TX, Psychological Corporation, 1996.",
"    </li>",
"    <li>",
"     Copeland, ED. Medications for Attention Disorders and Related Medical Problems, SPI Press, Atlanta, GA 1991.",
"    </li>",
"    <li>",
"     Conners, CK, Erhardt, et al. Conners' Adult ADHD Rating Scales (CAARS), Multihealth Systems, Inc., New York 1999.",
"    </li>",
"    <li>",
"     World Health Organization. ASRS-VI.I Screener 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/41\">",
"      McCann BS, Scheele L, Ward N, Roy-Byrne P. Discriminant validity of the Wender Utah Rating Scale for attention-deficit/hyperactivity disorder in adults. J Neuropsychiatry Clin Neurosci 2000; 12:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/42\">",
"      Sachs GS, Baldassano CF, Truman CJ, Guille C. Comorbidity of attention deficit hyperactivity disorder with early- and late-onset bipolar disorder. Am J Psychiatry 2000; 157:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/43\">",
"      Wilens TE. Attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2006; 163:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/44\">",
"      Shekim WO, Asarnow RF, Hess E, et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 1990; 31:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/45\">",
"      McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005; 162:1621.",
"     </a>",
"    </li>",
"    <li>",
"     Barkley, RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 2nd, Guilford, New York.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/48\">",
"      Naseem S, Chaudhary B, Collop N. Attention deficit hyperactivity disorder in adults and obstructive sleep apnea. Chest 2001; 119:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/49\">",
"      Ball, JD, Wooten, V, Crowell, TA. Adult ADHD and/or sleep apnea? Differential diagnostic considerations with six case studies. J Clin Psychol Med Settings 1999; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/50\">",
"      Okie S. ADHD in adults. N Engl J Med 2006; 354:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/51\">",
"      Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153:1147.",
"     </a>",
"    </li>",
"    <li>",
"     Wilens, TE, Spencer, et al. Phamacotherapy of adult ADHD. In: Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment, 2nd ed, Barakley, RA (Eds), Guilford, New York 1998. p.592.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/53\">",
"      A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073.",
"     </a>",
"    </li>",
"    <li>",
"     Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder, Agency for Healthcare Research and Quality, Rockville, MD 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/55\">",
"      Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J Nerv Ment Dis 2000; 188:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/56\">",
"      Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/57\">",
"      Lutton ME, Leach L, Triezenberg D. Clinical inquiries. Does stimulant therapy help adult ADHD? J Fam Pract 2003; 52:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/58\">",
"      Schweitzer JB, Cummins TK, Kant CA. Attention-deficit/hyperactivity disorder. Med Clin North Am 2001; 85:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/59\">",
"      Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001; 58:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/60\">",
"      Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/61\">",
"      Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/62\">",
"      Drugs for treatment of ADHD. Treat Guidel Med Lett 2006; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/63\">",
"      Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci 2001; 931:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/64\">",
"      Paterson R, Douglas C, Hallmayer J, et al. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 1999; 33:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/65\">",
"      Lisdexamfetamine dimesylate (Vyvanse) for ADHD. Med Lett Drugs Ther 2007; 49:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/66\">",
"      Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/67\">",
"      Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/68\">",
"      Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005; 66:253.",
"     </a>",
"    </li>",
"    <li>",
"     Spencer TJ, Biederman J, Wilen T. of ADHD with antidepressants. In: Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment, 2nd ed, Barkley RA (Ed), Guilford, New York 1998. p.522.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/70\">",
"      Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 1998; 59 Suppl 7:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/71\">",
"      Vastag B. Pay attention: ritalin acts much like cocaine. JAMA 2001; 286:905.",
"     </a>",
"    </li>",
"    <li>",
"     Manufacturer's prescribing information for lisdexamfetamine. www.vyvanse.com/pdf/prescribing_information.pdf.",
"    </li>",
"    <li>",
"     Spencer, TJ, Biederman, J, Wilen, T. Pharmacotherapy of ADHD with antidepressants. In: Barkley, RA (ed), Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment, 2nd ed, New York, Guilford, 1998, p. 522.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/74\">",
"      Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/75\">",
"      Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005; 57:793.",
"     </a>",
"    </li>",
"    <li>",
"     Strattera, package insert, Eli Lilly and Company, November, 2002.",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2005/safety05.htm#Strattera (Accessed October 5, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/78\">",
"      Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53:112.",
"     </a>",
"    </li>",
"    <li>",
"     New warning for strattera. FDA Talk Paper, December 17, 2004, www.fda.gov/bbs/topics/ANSWERS/2004/ANS01335.html (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/80\">",
"      Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/81\">",
"      Arnold LE. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). Ann N Y Acad Sci 2001; 931:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/82\">",
"      Higgins ES. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Pract 1999; 48:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/83\">",
"      Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/84\">",
"      Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/85\">",
"      Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 2008; 165:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/86\">",
"      Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/87\">",
"      Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005; 43:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/88\">",
"      Stevenson CS, Whitmont S, Bornholt L, et al. A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder. Aust N Z J Psychiatry 2002; 36:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/89\">",
"      Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010; 304:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/90\">",
"      Solanto MV, Marks DJ, Wasserstein J, et al. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry 2010; 167:958.",
"     </a>",
"    </li>",
"    <li>",
"     Searight, HR. Marriage and Intimacy. In: Jones, CB, Searight, HR, Urban, M (eds), Parent Articles on AD/HD, San Antonio, TX, Communication Skill Builders 1999. p.186.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32761/abstract/92\">",
"      Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am Fam Physician 2000; 62:2077.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1232 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32761=[""].join("\n");
var outline_f31_63_32761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES AND DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rating scales",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychiatric conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Stimulant preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cardiovascular side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Abuse potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Atomoxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Choice of pharmacotherapy agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Meta-cognitive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1232|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?22/39/23154\" title=\"form 1\">",
"      Adult ADHD screening tool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/27/11709\" title=\"table 1\">",
"      DSM-IV-TR criteria for ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/7/11387\" title=\"table 2\">",
"      Utah criteria for ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/32/23054\" title=\"table 3\">",
"      Drugs for ADHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4954?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40824?source=related_link\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_63_32762="Pharmacologic treatment of Parkinson disease";
var content_f31_63_32762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic treatment of Parkinson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32762/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32762/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32762/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/63/32762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/63/32762/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/63/32762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The array of pharmacologic and surgical treatments available for the treatment of idiopathic (or Lewy body) Parkinson disease (PD) is broader than for any other degenerative disease of the central nervous system. Management of individual patients requires careful consideration of a number of factors including the patient's symptoms and signs, age, stage of disease, degree of functional disability, and level of physical activity and productivity. Treatment can be divided into pharmacologic, nonpharmacologic, and surgical therapy. A useful algorithm for the management of PD has been published by the American Academy of Neurology (AAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacologic treatment of PD can be further divided into neuroprotective and symptomatic therapy. In practice, nearly all of the available treatments are symptomatic in nature and do not appear to slow or reverse the natural course of the disease. However, several potential neuroprotective agents for PD have shown some promise in animals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    humans and are undergoing further investigation. Neuroprotective therapy for PD is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15863?source=see_link\">",
"     \"Neuroprotective therapy for Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The routine medical management of PD is reviewed here. The nonpharmacologic management of PD, including education, support, exercise, and nutrition, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4277?source=see_link\">",
"     \"Nonpharmacologic management of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of advanced PD, particularly the complications associated with long-term levodopa therapy, and management of the comorbid problems including daytime sleepiness, hallucinations, and psychosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=see_link\">",
"     \"Motor fluctuations and dyskinesia in Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32105?source=see_link\">",
"     \"Surgical treatment of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21784?source=see_link\">",
"     \"Management of comorbid problems associated with Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correct diagnosis is fundamental to the appropriate therapy of PD, although the same menu of antiparkinson drugs is used to treat all of the various parkinsonian syndromes. The diagnosis of PD is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26089?source=see_link\">",
"     \"Diagnosis of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate symptomatic medical therapy in patients with PD is determined by the degree to which the patient is functionally impaired. The timing of this decision varies greatly among patients but is influenced by a number of factors, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The effect of disease on the dominant hand",
"     </li>",
"     <li>",
"      The degree to which the disease interferes with work, activities of daily living, or social and leisure function",
"     </li>",
"     <li>",
"      The presence of significant bradykinesia or gait disturbance",
"     </li>",
"     <li>",
"      Personal philosophy regarding the use of drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major drugs available for symptomatic therapy include (",
"    <a class=\"graphic graphic_table graphicRef69053 \" href=\"mobipreview.htm?37/53/38748\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Levodopa",
"     </li>",
"     <li>",
"      MAO B inhibitors",
"     </li>",
"     <li>",
"      Dopamine agonists",
"     </li>",
"     <li>",
"      COMT inhibitors",
"     </li>",
"     <li>",
"      Anticholinergic agents",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Either levodopa or a dopamine agonist (DA) can be used initially for patients who require symptomatic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Practitioners should always try to find the lowest but still effective dose of dopaminergic medication, either singly or in combination, for patients with PD, each of whom must be evaluated and managed in a highly individual way.",
"   </p>",
"   <p>",
"    In addition to these agents, low-dose estrogen may be helpful as adjunctive therapy in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Swallowing restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PD can go without antiparkinson medications when oral intake is temporarily restricted (eg, when perioperative, or when NPO for testing), or when seriously ill. In patients who are critically ill and bedbound, the parkinsonian symptoms are typically overshadowed by the burden of other medical problems, and antiparkinson medications may not provide any clear benefit.",
"   </p>",
"   <p>",
"    There have been reports of patients with PD who developed neuroleptic malignant syndrome in the context of sudden withdrawal of levodopa or dopamine agonists. However, the occurrence of neuroleptic malignant syndrome in this situation is highly unusual and is typically of more theoretical than real concern. Brief withdrawals (ie, for &lt;24 hours) of these medications under careful supervision during hospitalization should not be an issue.",
"   </p>",
"   <p>",
"    When treatment is still desired for patients who are NPO, options include transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/45/5846?source=see_link\">",
"     rotigotine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    by injection or continuous infusion. The use of apomorphine requires a test dose prior to ongoing treatment. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Dopamine agonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with dysphagia, orally disintegrating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    (Parcopa) is a potential treatment option. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Formulations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LEVODOPA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levodopa (L-dopa) is well established as the most effective drug for the symptomatic treatment of idiopathic or Lewy body PD. It is particularly effective for the management of akinetic symptoms and should be introduced when these become disabling and are uncontrolled by other antiparkinsonian drugs. Tremor and rigidity can also respond to levodopa therapy, but postural instability is less likely to do so.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levodopa is combined with a peripheral decarboxylase inhibitor to block its conversion to dopamine in the systemic circulation and liver (before it crosses the blood-brain barrier) in order to prevent nausea, vomiting, and orthostatic hypotension. In the United States, the decarboxylase inhibitor is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"     carbidopa",
"    </a>",
"    . The combination drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    (immediate-release Sinemet) is available in tablets of",
"    <span class=\"nowrap\">",
"     10/100,",
"    </span>",
"    <span class=\"nowrap\">",
"     25/100,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     25/250",
"    </span>",
"    mg, with the numerator referring to carbidopa and the denominator referring to the levodopa dose. An immediate-release formulation of carbidopa-levodopa (Parcopa) is available that dissolves on the tongue and can be taken without water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/7\">",
"     7",
"    </a>",
"    ], but there are no published studies of this formulation, and its time of onset of action is not different from Sinemet.",
"   </p>",
"   <p>",
"    In Europe, benserazide is the peripheral decarboxylase inhibitor. The combination drug benserazide-levodopa (Madopar or Prolopa) is available in",
"    <span class=\"nowrap\">",
"     25/100",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     50/200",
"    </span>",
"    mg tablets. Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    (Sinemet) and benserazide-levodopa (Prolopa) are available in Canada.",
"   </p>",
"   <p>",
"    Controlled-release formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    and benserazide-levodopa are available as Sinemet CR and Madopar HBS, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should begin with small doses, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    (Sinemet)",
"    <span class=\"nowrap\">",
"     25/100",
"    </span>",
"    mg, one-half tablet two to three times daily with meals (",
"    <a class=\"graphic graphic_table graphicRef69053 \" href=\"mobipreview.htm?37/53/38748\">",
"     table 1",
"    </a>",
"    ). Tolerance for the appropriate starting dose must be assessed individually. Once initiated without side effects, the total daily dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"     carbidopa",
"    </a>",
"    -levodopa can be titrated carefully upward over several weeks to a full tablet of",
"    <span class=\"nowrap\">",
"     25/100",
"    </span>",
"    mg three times daily as tolerated. Elderly patients or those with dementia should begin with smaller doses and slower titration because of their increased susceptibility to psychiatric side effects.",
"   </p>",
"   <p>",
"    The usual practice is to titrate to the lowest levodopa dose that produces a useful clinical response. This varies from patient to patient, but at the start it is typically in the vicinity of 300 to 600 mg of levodopa daily. The vast majority of patients with idiopathic PD will enjoy a significant therapeutic response to moderate doses of levodopa (300 to 600 mg daily). Complete absence of response to a levodopa dose of 1000 to 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    suggests that the original diagnosis of PD may be incorrect and that one of the other parkinsonian syndromes, such as multiple system atrophy, progressive supranuclear palsy, or vascular parkinsonism should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26089?source=see_link\">",
"     \"Diagnosis of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Controlled or sustained release levodopa preparations are less completely absorbed and require a dose up to 30 percent higher to achieve an equivalent clinical effect. The peak clinical effect of each tablet is typically less than for immediate release preparations, since controlled release formulations reach the brain more slowly over time. This presents a disadvantage in assessing the response of patients just initiating therapy. As a result, it is recommended that therapy be started with an immediate release preparation with a subsequent switch to controlled release if desired. Both the immediate and the controlled release formulations appear to maintain a similar level of symptom control after several years of use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients taking levodopa for the first time should take each dose with a meal or snack to avoid nausea, a common early side effect. Patients with more advanced disease, especially those with motor fluctuations, often notice that a dose of levodopa is more effective if taken on an empty stomach 30 minutes before or one hour after meals due to reduced competition with other amino acids for gastrointestinal absorption.",
"   </p>",
"   <p>",
"    Small starting doses of levodopa of less than",
"    <span class=\"nowrap\">",
"     25/100",
"    </span>",
"    mg three times daily combined with a decarboxylase inhibitor (eg, Sinemet, Madopar, or Prolopa) are more likely to cause nausea because of inadequate amounts of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"     carbidopa",
"    </a>",
"    ; this can be managed by administering supplemental doses of carbidopa or by use of antiemetics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/63/4085?source=see_link\">",
"     trimethobenzamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    (not available in the United States) taken prior to Sinemet. Phenothiazine antiemetics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    should be avoided because they are dopamine receptor blockers that can aggravate parkinsonian symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea, somnolence, dizziness, and headache are among the more common early side effects that may accompany treatment with levodopa, but they are not likely to be serious in most patients. More serious adverse reactions to levodopa (mainly in older patients) may include confusion, hallucinations, delusions, agitation, and psychosis.",
"   </p>",
"   <p>",
"    Levodopa may also induce a mild to moderate elevation in serum homocysteine levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/9-12\">",
"     9-12",
"    </a>",
"    ], which in turn may be associated with an increased risk of hip fractures in elderly patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H27#H27\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Possible risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, there is some preliminary evidence suggesting that levodopa exposure in patients with idiopathic PD is associated with elevated methylmalonic acid levels and possibly a higher than expected incidence of sensorimotor peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compulsive dopaminergic drug use has been reported in patients taking dopamine agonists, typically in conjunction with levodopa therapy. However, it is unclear that these behavioral issues arise with any frequency with levodopa monotherapy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Dopaminergic dysregulation syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Motor fluctuations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial number of patients develop levodopa-induced complications within several years of starting levodopa. These include motor fluctuations (the wearing-off phenomenon), involuntary movements known as dyskinesia, abnormal cramps and postures of the extremities and trunk known as dystonia, and a variety of complex fluctuations in motor function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=see_link\">",
"     \"Motor fluctuations and dyskinesia in Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is estimated that such motor complications occur in at least 50 percent of patients after 5 to 10 years of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/1\">",
"     1",
"    </a>",
"    ]. In the large group of patients with early PD studied in the DATATOP study, motor complications occurred in 30 percent after only two years of treatment with levodopa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/17\">",
"     17",
"    </a>",
"    ]. However, in a study of early PD, the prevalence of motor complications was only 20 percent after five years of treatment with levodopa given in relatively low doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, motor complications are more common in patients with young-onset PD compared with older onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one population-based study that compared patients who were 40 to 59 years of age at PD onset with those who were older than 70 years of age at PD onset, the corresponding five-year incidence of dyskinesia was 50 versus 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective data from a study of the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    and levodopa on early PD (the CALM-PD study) suggest that the earlier occurrence of motor fluctuations in the course of PD is associated with higher cumulative levodopa doses and higher cumulative levodopa-equivalent doses (ie, levodopa plus the dopamine agonist pramipexole) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast, prospective data from the same study suggest that a later onset of motor fluctuations in PD is associated with initial treatment with pramipexole rather than levodopa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors concluded that \"higher doses of dopaminergic medications than necessary to effectively control parkinsonian symptoms should be avoided,\" but noted that some patients with worse (ie, more rapidly progressive) disease may require high doses of dopaminergic medications to manage symptoms and therefore may be at greater risk for the development of motor complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/21\">",
"     21",
"    </a>",
"    ]. However, they noted that motor complications do not necessarily cause clinically significant functional impairment and can potentially be managed.",
"   </p>",
"   <p>",
"    It has been proposed that the increase in motor fluctuations over time is most likely due to progressive degeneration of nigrostriatal dopamine terminals, which increasingly limits the normal physiologic uptake and release of dopamine, thereby leading to reduced buffering of the natural fluctuations in plasma levodopa levels that occur due to levodopa's 90-minute pharmacologic half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/1\">",
"     1",
"    </a>",
"    ]. Controlled release preparations are useful for management of these fluctuations. However, in one report, the use of Sinemet CR three times daily (in an effort to provide more continuous stimulation of dopamine receptors) from the start of therapy was not associated with fewer motor complications compared with immediate release Sinemet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been longstanding concern among some clinicians that levodopa causes motor fluctuations and dyskinesia by its potential to promote oxidative stress and accelerated neurodegeneration, rather than by the change in levodopa pharmacodynamics that occurs with natural progression of the underlying disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Therefore, it is commonly proposed that the initiation of levodopa be delayed until symptoms significantly interfere with function. Others contend, however, that there is no convincing evidence that levodopa is itself responsible for late motor complications, and that delay of treatment unnecessarily deprives patients of therapeutic benefit early in the disease, when the potential for sustained improvement is greatest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, practitioners should always try to find the lowest but still effective dose of dopaminergic medication, either singly or in combination, for patients with PD, each of whom must be evaluated and managed according to his or her individual needs.",
"   </p>",
"   <p>",
"    Acute akinesia is a sudden exacerbation of PD characterized by an akinetic state that lasts for several days and does not respond to treatment with antiparkinson medication. This phenomenon is very different from the more common wearing \"off\" effects and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=see_link&amp;anchor=H11#H11\">",
"     \"Motor fluctuations and dyskinesia in Parkinson disease\", section on 'Acute akinesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neurotoxic versus neuroprotective effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concern that prolonged use of levodopa may directly hasten the degeneration of dopamine neurons in the substantia nigra by promoting the generation of free radicals and oxidative stress is one rationale for delaying the use of levodopa in the treatment of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/27\">",
"     27",
"    </a>",
"    ]. Another more compelling reason for delaying the use of levodopa is to possibly postpone the appearance of motor complications such as dyskinesia and motor fluctuations. The evidence regarding potential effects of levodopa on dopaminergic neurons is summarized by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In vitro, levodopa is toxic to cultured dopamine neurons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/28\">",
"       28",
"      </a>",
"      ]. In contrast, levodopa does not damage dopamine neurons in tissue culture in presence of glial cells, in normal humans (who do not have PD), or in intact animals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective neuropathologic study of patients with PD, the cumulative lifetime dose of levodopa did not correlate with disease pathology as measured by neuronal cell counts in the substantia nigra or by Lewy body density in the cortex and substantia nigra [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One experimental study found that levodopa increased neuronal damage in animals with partial injury to dopaminergic neurons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/31\">",
"       31",
"      </a>",
"      ]. However, this was not confirmed in subsequent reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 1998 consensus conference reached the following conclusions, which remain relevant today [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/34\">",
"       34",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There is no evidence that levodopa causes neuronal death in animal models of parkinsonism",
"     </li>",
"     <li>",
"      The relevance of in vitro studies of levodopa toxicity to clinical use of levodopa is highly uncertain",
"     </li>",
"     <li>",
"      There is no evidence that chronic administration of levodopa exacerbates the degenerative process in PD",
"     </li>",
"     <li>",
"      Late motor complications arise due to the combination of progressive degeneration of dopamine neurons and the reversible effects of levodopa administration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the ELLDOPA trial suggest that levodopa, rather than being neurotoxic, either slows the progression of PD or has a prolonged benefit even after the drug has been stopped. The ELLDOPA trial examined 361 patients with newly diagnosed PD and randomly assigned them to either one of three",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"       carbidopa-levodopa",
"      </a>",
"      doses",
"      <span class=\"nowrap\">",
"       (12.5/50",
"      </span>",
"      mg;",
"      <span class=\"nowrap\">",
"       25/100",
"      </span>",
"      mg;",
"      <span class=\"nowrap\">",
"       50/200",
"      </span>",
"      mg) given three times daily or to placebo for 40 weeks, followed by withdrawal of treatment for two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At 42 weeks, when underlying motor signs theoretically would be unmasked as a result of the two week washout, all groups assigned to levodopa showed significantly less worsening in the symptoms of parkinsonism, as measured by the UPDRS (",
"      <a class=\"graphic graphic_table graphicRef68974 \" href=\"mobipreview.htm?33/46/34530\">",
"       table 2",
"      </a>",
"      ), than did the placebo group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients receiving the highest levodopa dose (600",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      had the lowest (better) UPDRS score but, importantly, also had significantly more dyskinesia. Hypertonia, infection, headache, and nausea were also more common than in the placebo group. Therefore, the clinical data suggested, surprisingly, that the use of levodopa for 40 weeks was neuroprotective.",
"     </li>",
"     <li>",
"      On the other hand, imaging data from a substudy of 116 patients supported observations from two previous studies that levodopa treatment is associated with a greater decline in basal ganglia uptake of dopamine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/35\">",
"       35",
"      </a>",
"      ]. The substudy used single photon emission computed tomography (SPECT) to assess striatal dopamine by measuring [123I]beta-CIT uptake, and showed that patients taking levodopa had a greater reduction in nigrostriatal dopamine transport compared with those on placebo. Once again, the question of levodopa toxicity versus levodopa-related down regulation of the dopamine transporter receptors could not be resolved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In conclusion, the debate over the potential neuroprotective versus neurotoxic effects of levodopa remains unresolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], but the weight of the evidence accumulated to date shows that long term use of levodopa is not a hazard, especially in light of its superiority over all other pharmacotherapies.",
"   </p>",
"   <p>",
"    Further clinical trials are needed to determine the effects of levodopa on the progression of PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/27\">",
"     27",
"    </a>",
"    ]. In the meantime, levodopa remains the most effective therapy for PD, and should be introduced if there is sufficient compromise of quality of life or functional ability to warrant treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MAO B INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     Selegiline",
"    </a>",
"    (Eldepryl), a selective monoamine oxidase (MAO) type B inhibitor (",
"    <a class=\"graphic graphic_table graphicRef69053 \" href=\"mobipreview.htm?37/53/38748\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/38\">",
"     38",
"    </a>",
"    ], is modestly effective as symptomatic treatment for PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/39\">",
"     39",
"    </a>",
"    ] and may have neuroprotective properties. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15863?source=see_link&amp;anchor=H2432865#H2432865\">",
"     \"Neuroprotective therapy for Parkinson disease\", section on 'Selegiline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many individuals, however,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    monotherapy does not produce a functionally significant benefit. However, the use of selegiline in early PD is a reasonable option as long as the patient understands its limitations.",
"   </p>",
"   <p>",
"    The selective MAO B inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/13/24791?source=see_link\">",
"     rasagiline",
"    </a>",
"    has neuroprotective properties in animal models and appears modestly effective as symptomatic treatment for PD in human clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15863?source=see_link&amp;anchor=H6#H6\">",
"     \"Neuroprotective therapy for Parkinson disease\", section on 'Rasagiline'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence supporting the symptomatic effect of MAO B inhibitors for PD comes from a 2004 meta-analysis that examined data from 17 randomized trials involving 3525 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/42\">",
"     42",
"    </a>",
"    ]. These individual trials compared MAO B inhibitors (predominately",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    ) with either levodopa or placebo (predominately placebo) in the treatment of early PD. Many of these trials were limited by short-term follow-up, poor reporting of results, and absence of quality of life data. With these limitations in mind, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data for clinical rating scales were available from six trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"       selegiline",
"      </a>",
"      ; treatment with MAO B inhibitors was associated with significantly better total scores, motor scores, and activities of daily living scores on the UPDRS (",
"      <a class=\"graphic graphic_table graphicRef68974 \" href=\"mobipreview.htm?33/46/34530\">",
"       table 2",
"      </a>",
"      ) at three months compared with controls.",
"     </li>",
"     <li>",
"      Data on the need for levodopa were available from eight studies with a median follow-up of 13 months; treatment with MAO B inhibitors was associated with a reduction in the need for additional levodopa compared with controls.",
"     </li>",
"     <li>",
"      Data on motor complications were available from five trials; treatment with MAO B inhibitors was associated with a modest reduction in the development of motor fluctuations compared with controls. However, MAO B treatment was not associated with a significant difference in the incidence of dyskinesia.",
"     </li>",
"     <li>",
"      Data on mortality were available from 10 trials, nine of which involved",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"       selegiline",
"      </a>",
"      . MAO B inhibitor treatment was not associated with increased mortality compared with controls, in contrast to one observational study from the United Kingdom that showed increased mortality in patients using selegiline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/43\">",
"       43",
"      </a>",
"      ]. The results of the UK study have not been confirmed by subsequent reports, including an earlier meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/44-46\">",
"       44-46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent (2012) systematic review identified 12 randomized controlled trials comparing MAO B inhibitors (11 trials used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    ) with placebo for the treatment of early PD in 2514 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/47\">",
"     47",
"    </a>",
"    ]. The findings supported a small symptomatic benefit of treatment on parkinsonian impairment and disability scores at one year.",
"   </p>",
"   <p>",
"    Additional evidence supporting the long-term symptomatic benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    for PD comes from the continuation phase of a randomized controlled trial involving 157 patients with PD, in which patients who were initially assigned to selegiline in the earlier phase of the study were treated with combined selegiline and levodopa, while those initially assigned to placebo were treated with combined placebo and levodopa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/48\">",
"     48",
"    </a>",
"    ]. At seven years, treatment with the combination of selegiline and levodopa was associated with significantly better symptom control than treatment with placebo and levodopa.",
"   </p>",
"   <p>",
"    Uncertainty remains about the relative risks and benefits of MAO B inhibitors, as few trials compared them with other antiparkinson medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/42,49\">",
"     42,49",
"    </a>",
"    ]. Comparative data are particularly lacking for the dopamine agonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    used in DATATOP was 5 mg twice daily, with the second dose given at noon to avoid insomnia. However, lower doses are sufficient to induce MAO B inhibition, and 5 mg once daily in the morning is currently recommended. Doses higher than 10 mg daily are of no additional benefit and may result in nonselective MAO inhibition, thereby placing the patient at risk of hypertensive crisis due to dietary interactions with tyramine containing foods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea and headache are associated with the use of MAO B inhibitors, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    or its amphetamine metabolites can cause insomnia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     Selegiline",
"    </a>",
"    often causes confusion in the elderly, thereby limiting its use in patients with late-onset disease. As previously mentioned, selegiline enhances the effect of levodopa by slowing its oxidative metabolism. Thus, it may increase levodopa-induced side effects such as dyskinesia and psychiatric toxicity (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Levodopa'",
"    </a>",
"    above). However, the need for continued selegiline is questionable once patients have reached the point of requiring levodopa.",
"   </p>",
"   <p>",
"    Serious adverse reactions have rarely occurred following the concomitant use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    with tricyclic antidepressants or selective serotonin reuptake inhibitors (SSRIs). In practice, the vast majority of patients on these combinations are able to tolerate them for years without problems. However, the Physicians' Desk Reference (PDR) warns not to use selegiline with either tricyclics or SSRIs. The possible interaction of SSRI and MAO B inhibitor treatment in patients with PD is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21784?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of comorbid problems associated with Parkinson disease\", section on 'Concerns with SSRI use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommended time intervals to avoid drug interactions when switching or discontinuing antidepressants and MAO inhibitors are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=see_link&amp;anchor=H11#H11\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Switching to or from MAOIs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike nonselective MAO inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    does not precipitate a hypertensive crisis in patients who concomitantly ingest tyramine-containing foods. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DOPAMINE AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dopamine agonists (DAs) are a group of synthetic agents that directly stimulate dopamine receptors. The drugs currently approved by the United States Food and Drug Administration (FDA) include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/45/5846?source=see_link\">",
"     rotigotine",
"    </a>",
"    , and injectable",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69053 \" href=\"mobipreview.htm?37/53/38748\">",
"     table 1",
"    </a>",
"    ). Pergolide has been voluntarily withdrawn from the United States market and is best avoided because it is associated with a risk of cardiac valve problems (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Valvular heart disease'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"     Apomorphine",
"    </a>",
"    and lisuride are additional DAs that can be administered parenterally for \"rescue therapy\" in patients experiencing sudden akinetic episodes. Lisuride is not currently approved in the United States, but is available in Europe. Injectable apomorphine has been approved by the United States FDA for treatment of motor fluctuations in PD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/50\">",
"     50",
"    </a>",
"    ]. Apomorphine infusion pumps may also be useful, but are not available in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=see_link&amp;anchor=H5#H5\">",
"     \"Motor fluctuations and dyskinesia in Parkinson disease\", section on 'Dopamine agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    (Sinemet), these drugs are direct agonists that do not require metabolic conversion, do not compete with amino acids for transport across the gut or into the brain, and do not depend upon neuronal uptake and release. An additional advantage over immediate-release forms of levodopa is the longer duration of action of most of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonists (DAs) were initially introduced as adjunctive treatment for advanced PD complicated by reduced levodopa response, motor fluctuations, dyskinesia, and other adverse effects of levodopa. However, the hypothetical concern that free radicals generated by the oxidative metabolism of dopamine contribute further to the degeneration of dopaminergic neurons has prompted some investigators, despite lack of conclusive evidence, to advocate the early use of DAs as an levodopa-sparing strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With this approach, treatment with levodopa can be postponed and saved for a later time in the course of the disease, when disability worsens and the less effective agonists no longer provide adequate benefit. This strategy is based upon the unproven concept that the long-term duration of a given patient's responsiveness to levodopa is finite and that the drug, like money in a savings or retirement account, should be rationed. However, whether reduced responsiveness to levodopa over time is due to a decline in drug response or progression of underlying PD is currently uncertain.",
"   </p>",
"   <p>",
"    Given the potential that DAs are associated with fewer motor fluctuations and the evidence that there is a higher incidence of levodopa-related dyskinesia in young-onset PD, some experts suggest using DAs as initial treatment for PD in patients younger than age 60, and using the more effective agent levodopa in patients 60 and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/53\">",
"     53",
"    </a>",
"    ], although other factors should be weighed in making this treatment decision. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Motor fluctuations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Effectiveness of DAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled trials have shown that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , pergolide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    are all effective in patients with advanced PD complicated by motor fluctuations and dyskinesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=see_link&amp;anchor=H5#H5\">",
"     \"Motor fluctuations and dyskinesia in Parkinson disease\", section on 'Dopamine agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other studies have found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    , transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/45/5846?source=see_link\">",
"     rotigotine",
"    </a>",
"    , and pergolide are effective as monotherapy in patients with early disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/23,54-60\">",
"     23,54-60",
"    </a>",
"    ]. However, DAs are ineffective in patients who have shown no therapeutic response to levodopa.",
"   </p>",
"   <p>",
"    The utility of DAs in early PD is supported by the results of a systematic review and meta-analysis published in 2008 that identified 29 eligible trials involving 5247 subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/61\">",
"     61",
"    </a>",
"    ]. Included trials compared DA therapy (with or without levodopa) versus placebo",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    levodopa. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 16 trials that compared a DA (plus or minus supplementation with levodopa) versus levodopa, patients assigned to DA treatment were less likely to develop dyskinesia (odds ratio [OR] 0.51, 95% CI 0.43-0.59), dystonia (OR 0.64, 95% CI 0.51-0.81) or motor fluctuations (OR 0.75, 95% CI 0.63-0.90) than those assigned to levodopa.",
"     </li>",
"     <li>",
"      In contrast, symptomatic control of PD appeared to be better with levodopa than with DAs. Inconsistent and incomplete data reporting prevented meta-analysis of motor symptom control. However, patients assigned to levodopa had significantly greater improvement in clinician-rated disability in four of the 11 trials that compared DAs with levodopa, while a nonsignificant improvement favoring levodopa was reported in five of the remaining seven trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reduction in motor complications with DAs compared with levodopa is further illustrated by findings from individual trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial found that the cumulative incidence of dyskinesia over five years was 20 percent in patients assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      (plus or minus supplementation with levodopa) and 45 percent in patients assigned to levodopa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another randomized trial found a similar 22 percent absolute reduction in the development of dyskinesia and a 16 percent reduction in wearing \"off\" in patients assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       pramipexole",
"      </a>",
"      compared with those assigned to levodopa (",
"      <a class=\"graphic graphic_figure graphicRef73247 \" href=\"mobipreview.htm?22/30/23023\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/23\">",
"       23",
"      </a>",
"      ]. On the other hand, patients assigned to levodopa had lower incidences of freezing, somnolence, and leg edema (the latter two attributable to side effects of pramipexole), and had better symptomatic control than those assigned to pramipexole. Both treatments resulted in similar quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there is evidence from several clinical trials and a meta-analysis that early DA monotherapy postpones the future onset of motor complications. This may simply be because DAs are less potent than levodopa in their effects on motor function. In support of this, the benefit occurs at the expense of reduced efficacy when compared with levodopa. In practice, while symptoms can be controlled initially with DAs, few patients with progressive disease can be satisfactorily maintained on DA monotherapy for more than a few years before levodopa is needed.",
"   </p>",
"   <p>",
"    The few studies that have compared the efficacy of various DAs with each other have found either no significant difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/62,63\">",
"     62,63",
"    </a>",
"    ] or only mild superiority of one agent over another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DAs generally require administration at least three times a day at maintenance doses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       Bromocriptine",
"      </a>",
"      is usually started at 1.25 mg twice a day; the dose is increased at two to four week intervals by 2.5 mg a day. Most patients can be managed on 20 to 40 mg daily in three to four divided doses, although total daily doses as high as 90 mg can be used.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       Pramipexole",
"      </a>",
"      is usually started at 0.125 mg three times a day. The dose should be increased gradually by 0.125 mg per dose every five to seven days. Most patients can be managed on total daily doses of 1.5 to 4.5 mg.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"       Ropinirole",
"      </a>",
"      is usually started at 0.25 mg three times a day. The dose should be increased gradually by 0.25 mg per dose each week for four weeks to a total daily dose of 3 mg. Most patients can be managed on this dose. After week four, the ropinirole dose may be increased weekly by 1.5 mg a day up to a maximum total daily dose of 24 mg. Benefit most commonly occurs in the dosage range of 12 to 16 mg per day.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       Pramipexole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      are now both available in sustained release formulations; these are useful for convenience and for avoiding peaks and troughs in plasma levels.",
"     </li>",
"     <li>",
"      Transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/45/5846?source=see_link\">",
"       rotigotine",
"      </a>",
"      is a once-daily patch that is usually started at 2",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours and titrated weekly by increasing the patch size in 2",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hour increments to a dose of 6",
"      <span class=\"nowrap\">",
"       mg/24",
"      </span>",
"      hours. Rotigotine should",
"      <strong>",
"       not",
"      </strong>",
"      be stopped abruptly, because sudden withdrawal of DAs has been associated (rarely) with a syndrome resembling neuroleptic malignant syndrome or akinetic crisis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"       Apomorphine",
"      </a>",
"      may be administered either as intermittent rescue injections or as continuous infusions to treat \"off\" episodes or levodopa-induced motor fluctuations. A challenge test dose must precede routine use. This is usually done with a 2 mg subcutaneous injection under medical supervision and monitoring of standing and supine blood pressure before the injection, and repeated at 20, 40, and 60 minutes after.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antiemetic therapy (eg, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/63/4085?source=see_link\">",
"     trimethobenzamide",
"    </a>",
"    ) is initiated three days prior to starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    and is usually continued for two months before reassessing need. However, the use of apomorphine is contraindicated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    and other serotonin receptor agonists commonly used to treat nausea and vomiting, as the combination may cause severe hypotension and loss of consciousness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, dopamine antagonists used to treat nausea and vomiting such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    should be avoided, as they may reduce the effectiveness of apomorphine.",
"   </p>",
"   <p>",
"    The usual starting dose for intermittent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    use, if the patient tolerates and responds to the test dose, is 2 mg. The dose may be increased by 1 mg per dose every two to four days to a maximum of 6 mg per dose. The average dosing frequency is three times daily and should not exceed five times a day dosing or a total daily dose of 20 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adverse effects of dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects caused by dopamine agonists (DAs) are similar to those of levodopa, including nausea, vomiting, sleepiness, orthostatic hypotension, confusion, and hallucinations. Peripheral edema is common with the chronic use of DAs but is rare in patients using levodopa alone. In the systematic review of 29 trials and 5247 patients cited above, those assigned to DA treatment were significantly more likely than patients assigned to levodopa therapy to develop side effects of edema, somnolence, constipation, dizziness, hallucinations, and nausea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, patients assigned to DA therapy were significantly more likely to discontinue treatment due to adverse events (OR 2.49, 95% CI 2.08-2.98).",
"   </p>",
"   <p>",
"    These adverse effects of DAs can usually be avoided by initiating treatment with very small doses and titrating to therapeutic levels slowly over several weeks. Patients intolerant of one DA may tolerate another. As with all of the antiparkinsonian drugs, elderly and demented patients are much more susceptible to psychiatric side effects.",
"   </p>",
"   <p>",
"    Accumulating evidence suggests that the use of DAs as a class may lead to compulsive use of dopaminergic drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impulse control disorders in a small percentage of patients taking these drugs. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Dopaminergic dysregulation syndrome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Impulse control disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is also evidence of a \"dopamine agonist withdrawal syndrome\" in some patients with PD who abruptly stop taking a DA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/67\">",
"     67",
"    </a>",
"    ]. Symptoms resemble those of cocaine withdrawal and include anxiety, panic attacks, depression, sweating, nausea, pain, fatigue, dizziness, and drug craving. These were refractory to other antiparkinson medications including levodopa and only responded to resuming the DA.",
"   </p>",
"   <p>",
"    The use of transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/45/5846?source=see_link\">",
"     rotigotine",
"    </a>",
"    is associated with skin site reactions, typically transient and mild to moderate in severity, but occasionally severe enough to result in discontinuation.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    DAs is also associated with a risk of valvular heart disease. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Valvular heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Adverse events with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    are usually mild and consist predominantly of cutaneous reactions and neuropsychiatric problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/50\">",
"     50",
"    </a>",
"    ]. The incidence of these problems is higher in patients receiving continuous infusion than in those receiving intermittent subcutaneous injections. Chest pain, angina, and orthostatic hypotension are more serious problems; orthostasis peaks 20 minutes after dosing and lasts at least 90 minutes. A test dose of apomorphine to establish tolerance and responsiveness is essential prior to routine administration.",
"   </p>",
"   <p>",
"    Ergot-related side effects such as Raynaud phenomenon, erythromelalgia, and retroperitoneal or pulmonary fibrosis are uncommon with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    and pergolide, and they do not occur at all with the nonergot agonists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/45/5846?source=see_link\">",
"     rotigotine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Dopamine receptor agonists decrease prolactin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/68\">",
"     68",
"    </a>",
"    ]. Thus, there is a potential for decreased milk production in postpartum women taking these agents, which are contraindicated in women who are breast feeding.",
"   </p>",
"   <p>",
"    The manufacturer of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    has issued a warning regarding somnolence that can occur abruptly and without premonition, particularly at a dose above 1.5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Patients with PD who drive are at particular risk of developing these \"sleep attacks\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/69\">",
"     69",
"    </a>",
"    ]. Patients should be warned of this potential side effect and asked about factors that may increase the risk of drowsiness, such as concomitant sedating medications, sleep disorders, and medications that increase pramipexole levels (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21784?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of comorbid problems associated with Parkinson disease\", section on 'Daytime sleepiness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Valvular heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mounting evidence suggests that treatment with pergolide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    is associated with a clinically and statistically significant risk of valvular heart disease, with lesions similar to those associated with carcinoid, ergot, and fenfluramine-induced valvular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/70-76\">",
"     70-76",
"    </a>",
"    ]. The risk of valvular heart disease appears to increase relative to the cumulative dose of pergolide or cabergoline. The mechanism is probably related to pergolide and cabergoline activation of serotonin (5-HT 2B type) receptors expressed on heart valves, which in turn leads to valvular overgrowth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nested case-control study from the United Kingdom involving a cohort of 11,417 patients taking antiparkinsonian drugs, 31 patients with newly diagnosed cardiac valve regurgitation were compared with 664 controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/73\">",
"       73",
"      </a>",
"      ]. The risk of cardiac valve regurgitation was significantly increased with current use of pergolide (incidence-rate ratio [IRR] 7.1, 95% CI 2.3-22.3) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      (IRR 4.9, 95% CI 1.5-15.6), but not with other DAs. The risk of cardiac valve regurgitation was increased only for patients taking pergolide or cabergoline for six months or longer, and was particularly increased for both medications at doses higher than 3 mg daily.",
"     </li>",
"     <li>",
"      In a case-control study from Italy involving 155 patients taking DAs for PD and 90 control subjects, the frequency of clinically important valve regurgitation determined by echocardiography was significantly higher in patients taking pergolide or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      compared with controls (23.4 and 28.6 versus 5.6 percent, respectively), but not in those taking nonergot DAs (0 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, pergolide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used as treatment for PD. In the United States, pergolide was voluntarily withdrawn from the market in March 2007 due to the potential risk of heart valve damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dopaminergic dysregulation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compulsive use of dopaminergic drugs develops in a small number of patients with PD and has been termed the dopaminergic dysregulation syndrome (DDS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DDS typically involves male patients with early onset PD who take increasing quantities of dopaminergic drugs despite increasingly severe drug-induced dyskinesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. DDS can be associated with a cyclical mood disorder characterized by hypomania or manic psychosis. Tolerance (or frank dysphoria) to the mood elevating effects of dopaminergic therapy develops, and a withdrawal state occurs with dose reduction or withdrawal. Impulse control disorders including hypersexuality and pathologic gambling may accompany DDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Impulse control disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A form of complex, prolonged, purposeless, and stereotyped behavior called punding also may be associated with DDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DDS appears to be uncommon but not rare. In a series of 202 patients with PD, criteria for DDS were fulfilled in seven (3.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/82\">",
"     82",
"    </a>",
"    ]. DDS may occur more frequently with dopaminergic agonists than with levodopa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/82\">",
"     82",
"    </a>",
"    ], but data are scarce. A small case-control study found that susceptibility factors for DDS included younger age at disease onset, higher novelty seeking personality traits, depressive symptoms, and alcohol intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of DDS is not well studied. Practitioners should limit dopaminergic dose increases when possible, particularly in patients who may have increased susceptibility to DDS. Continuous subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    infusions may be useful to suppress off-period dysphoria, and low doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    may be helpful for some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/83\">",
"     83",
"    </a>",
"    ]. Treatment of psychosis in patients with PD is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21784?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of comorbid problems associated with Parkinson disease\", section on 'Psychosis and hallucinations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Impulse control disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonist therapy may be associated with an increased risk of impulse control disorders including pathologic gambling, compulsive sexual behavior, or compulsive buying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. This issue is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Canadian case series of 297 patients with PD, the lifetime prevalence of pathologic gambling, hypersexuality, or compulsive shopping was 13.7 percent in patients on DAs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/86\">",
"       86",
"      </a>",
"      ]. The lifetime prevalence of pathologic gambling for all patients and for those receiving any DA was 3.4 and 7.2 percent, respectively, compared with a lifetime prevalence of 1.0 percent in the Ontario population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/87\">",
"       87",
"      </a>",
"      ]. There was a statistically significant association of pathologic gambling and hypersexuality with earlier PD onset and DA therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. In line with earlier retrospective studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/88,89\">",
"       88,89",
"      </a>",
"      ], pathologic gambling did not develop in patients receiving levodopa monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/87\">",
"       87",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22760?source=see_link\">",
"       \"Pathologic gambling\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another series of 272 patients with PD found that criteria for impulse control disorders, either anytime during the course of PD or currently active, were met by 6.6 and 4.0 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/90\">",
"       90",
"      </a>",
"      ]. The frequency of pathologic gambling, compulsive sexual behavior, and compulsive buying anytime during PD were 2.6, 2.6, and 1.5 percent, respectively. On multivariate analysis, significant predictors of an active impulse control disorder were use of a DA and a history of impulse control disorder symptoms before the onset of PD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective case series of 11 patients with PD who developed pathologic gambling linked to DA therapy, the pathologic gambling resolved with tapering or discontinuation of DA therapy in eight patients available for follow-up. Only one of 11 patients in the series met criteria for the dopaminergic dysregulation syndrome described above, although six patients simultaneously developed other inappropriate behaviors such as hypersexuality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Dopaminergic dysregulation syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A randomized crossover trial of 17 patients found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    (target dose 100 mg twice daily), administered as add-on to baseline antiparkinsonian medications, was effective for reducing or abolishing pathologic gambling in all treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/91\">",
"     91",
"    </a>",
"    ]. However, five patients dropped out of the trial due to side effects that included confusion, orthostatic hypotension, insomnia, and visual hallucinations. The high drop-out rate is consistent with the notion that amantadine may be poorly tolerated in patients with PD taking other antiparkinsonian medications. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Amantadine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMT INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catechol-O-methyl transferase (COMT) inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    (Tasmar) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    (Comtan) are useful as levodopa extenders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/92\">",
"     92",
"    </a>",
"    ]. They are ineffective when given alone, but they may prolong and potentiate the levodopa effect when given with a dose of levodopa. These medications are mainly used to treat patients with motor fluctuations who are experiencing end-of-dose wearing \"off\" periods. When given to patients without motor fluctuations, entacapone did not improve UPDRS motor scores (",
"    <a class=\"graphic graphic_table graphicRef68974 \" href=\"mobipreview.htm?33/46/34530\">",
"     table 2",
"    </a>",
"    ), but was associated with several improved quality of life measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=see_link&amp;anchor=H20#H20\">",
"     \"Motor fluctuations and dyskinesia in Parkinson disease\", section on 'Unpredictable \"off\" periods'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibition of catechol-O-methyl transferase reduces the peripheral (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    ) and central (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    ) methylation of levodopa and dopamine, which in turn increases the plasma half-life of levodopa, produces more stable plasma levodopa concentrations, and prolongs the therapeutic effect of each dose. Use of COMT inhibitors may allow a reduction in the total daily levodopa dose by as much as 30 percent. The net result is an increased levodopa effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/92,94\">",
"     92,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    is 100 mg three times daily; the clinical effect is evident immediately. The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    is one 200 mg tablet with each dose of levodopa, up to a maximum of eight doses per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    are due to increased dopaminergic stimulation and include dyskinesia, hallucinations, confusion, nausea, and orthostatic hypotension. The adverse effects are managed by lowering the dose of levodopa either before or after the addition of tolcapone. Diarrhea that is poorly responsive to antidiarrheal medications appears in approximately 5 percent of patients. An orange discoloration of the urine is a common but benign adverse event. Elevations in liver enzymes may rarely occur.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/47/33526?source=see_link\">",
"     Tolcapone",
"    </a>",
"    was removed from the market in Europe and Canada in 1998 after three reported deaths from hepatotoxicity in patients using tolcapone. The drug remained available in the United States with the recommendation that it be used for treatment of motor fluctuations only after other methods have been exhausted and with regular monitoring of ALT and AST levels. Tolcapone was reintroduced in Europe in 2006 with accumulating data suggesting that it has a negligible risk of severe or life-threatening hepatotoxicity when used appropriately with liver function monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. Its continued use in the United States has also been associated with a very low risk of hepatotoxicity when appropriately monitored with liver function tests for a period of six months after starting the drug.",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38501?source=see_link\">",
"     entacapone",
"    </a>",
"    are similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/47/33526?source=see_link\">",
"     tolcapone",
"    </a>",
"    , although entacapone has thus far not been associated with hepatotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ANTICHOLINERGICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine and acetylcholine are normally in a state of electrochemical balance in the basal ganglia. In PD, dopamine depletion produces a state of cholinergic sensitivity so that cholinergic drugs exacerbate and anticholinergic drugs improve parkinsonian symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Centrally acting anticholinergic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"     benztropine",
"    </a>",
"    have been used for many years in PD and continue to have a useful role (",
"    <a class=\"graphic graphic_table graphicRef69053 \" href=\"mobipreview.htm?37/53/38748\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/100\">",
"     100",
"    </a>",
"    ]. Other anticholinergic agents such as biperiden,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/11/36021?source=see_link\">",
"     orphenadrine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/43/19124?source=see_link\">",
"     procyclidine",
"    </a>",
"    produce similar effects and are more commonly used in Europe than the United States. Benztropine also may increase the effect of dopamine by inhibiting its presynaptic reuptake, but it is not known whether this contributes to its mechanism of action.",
"   </p>",
"   <p>",
"    Anticholinergic drugs are most useful as monotherapy in patients under age 70 with disturbing tremor who do not have significant akinesia or gait disturbance. They also may be useful in patients with more advanced disease who have persistent tremor despite treatment with levodopa or DAs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/1/6165?source=see_link\">",
"     Trihexyphenidyl",
"    </a>",
"    is the most widely prescribed anticholinergic agent, although there is little evidence to suggest that one drug in this class is superior to another. The starting dose of trihexyphenidyl is 0.5 to 1 mg twice daily, with a gradual increase to 2 mg three times daily.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"     Benztropine",
"    </a>",
"    traditionally is more commonly used by psychiatrists for the management of antipsychotic drug-induced parkinsonism; the usual dose is 0.5 to 2 mg twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of anticholinergic drugs are common and often limit their use. Elderly and cognitively impaired patients are particularly susceptible to memory impairment, confusion, and hallucinations and should not receive these drugs. When an anticholinergic drug is used to treat sialorrhea or urinary frequency, peripherally acting agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/4/14404?source=see_link\">",
"     propantheline",
"    </a>",
"    should be used, although confusion and hallucinations are not infrequent adverse effects with these drugs as well. Younger patients usually tolerate these agents better than the elderly, although some experience dysphoric symptoms, sedation, or memory impairment.",
"   </p>",
"   <p>",
"    Peripheral antimuscarinic side effects include dry mouth, blurred vision, constipation, nausea, urinary retention, impaired sweating, and tachycardia. Caution is advised in patients with known prostatic hypertrophy or closed-angle glaucoma. Discontinuation of anticholinergic drugs should be performed gradually to avoid withdrawal symptoms that may manifest as an acute exacerbation of parkinsonism, even in those in whom the clinical response has not seemed significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     AMANTADINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    is an antiviral agent that has mild antiparkinsonian activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/101\">",
"     101",
"    </a>",
"    ]. Its mechanism of action is uncertain; it is known to increase dopamine release, inhibit dopamine reuptake, stimulate dopamine receptors, and it may possibly exert central anticholinergic effects (",
"    <a class=\"graphic graphic_table graphicRef69053 \" href=\"mobipreview.htm?37/53/38748\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/102\">",
"     102",
"    </a>",
"    ]. Amantadine has N-methyl-D-aspartate (NMDA) receptor antagonist properties that may account for its therapeutic effect by interfering with excessive glutamate neurotransmission in the basal ganglia.",
"   </p>",
"   <p>",
"    In early uncontrolled clinical trials, two-thirds of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    monotherapy showed an improvement in akinesia, rigidity, and tremor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/101\">",
"     101",
"    </a>",
"    ]. Subsequent controlled studies demonstrated that it was more effective than anticholinergic drugs for akinesia and rigidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/103\">",
"     103",
"    </a>",
"    ]. The benefit induced by amantadine appears to be transient in some patients; it is best used as short-term monotherapy in those with mild disease. Amantadine is of little benefit when added to levodopa, although the addition of levodopa to amantadine causes significant additive improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    in divided doses of 200 to 400 mg a day may reduce the intensity of levodopa-induced dyskinesia and motor fluctuations in patients with PD. Although the published randomized trials on amantadine in advanced PD are limited by serious methodological flaws and small numbers of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/105\">",
"     105",
"    </a>",
"    ], experience has shown that individual patients with advanced PD who have motor fluctuations and dyskinesia can benefit dramatically, at least for a while, from the addition of amantadine to a regimen of levodopa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    in early PD is 200 to 300 mg daily; there is no evidence that larger doses are of additional benefit. The main advantage of this agent is a low incidence of side effects. It is excreted unchanged in the urine and should be used with caution in the presence of renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral side effects include livedo reticularis and ankle edema, which are rarely severe enough to limit treatment. Confusion, hallucinations, and nightmares occur infrequently, but unpredictably, even after long periods of use without side effects. These effects are more likely when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    is used together with other antiparkinsonian drugs in older patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     ESTROGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose estrogen may be helpful as adjunctive therapy in postmenopausal women with motor fluctuations on antiparkinsonian medication. In one study, administration of Premarin 0.625 mg daily for eight weeks significantly improved \"on\" time and motor control in such women, although it did not result in global improvement on a scale rating activities of daily living [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/63/32762/abstract/5\">",
"     5",
"    </a>",
"    ]. There is no evidence that estrogen has a specific effect on dopamine receptors; the benefit attributable to estrogen use may be related to an overall sense of well being.",
"   </p>",
"   <p>",
"    It is not clear if these results would be similar in women taking combined",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    therapy (necessary in women with an intact uterus). Furthermore, concerns about adverse effects associated with long-term",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    therapy may limit its use in PD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13954?source=see_link\">",
"       \"Patient information: Parkinson disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/8/34947?source=see_link\">",
"       \"Patient information: Medicines for Parkinson disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/63/30708?source=see_link\">",
"       \"Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Either levodopa or a dopamine agonist (DA) can be used initially for patients who require symptomatic therapy. Practitioners should always try to find the lowest but still effective dose of dopaminergic medication, either singly or in combination, for patients with PD, each of whom must be evaluated and managed in a highly individual way. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptomatic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Levodopa (combined with a peripheral decarboxylase inhibitor, ie, Sinemet, Madopar, or Prolopa) is the most effective symptomatic therapy for Parkinson disease (PD) and should be introduced when the patient and physician jointly decide that quality of life, particularly related to job performance or self care, is substantially compromised. However, levodopa is associated with a higher risk of dyskinesia than the DAs. There does not appear to be a benefit of initiating treatment with controlled release levodopa compared with the immediate release preparation, and the former may limit the ability to follow the initial response to therapy. As a result, it is recommended that therapy be initiated with an immediate release preparation with a subsequent switch to controlled release if indicated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Levodopa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the exception of pergolide and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      , the dopamine agonists are a useful group of drugs that may be employed either as monotherapy in early PD or in combination with other antiparkinsonian drugs for treatment of more advanced disease. They are ineffective in patients who show no response to levodopa. They possibly delay the need to initiate levodopa therapy and the subsequent appearance of levodopa dyskinesia and motor fluctuations, but at the risk of slightly less efficacy and increased adverse effects. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dopamine agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pergolide and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      should not be used for PD because of the risk of valvular heart disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Valvular heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is reasonable to initiate therapy with a DA in younger patients (age &lt;65) with PD, and with levodopa in elderly patients (age &gt;65). However, there are exceptions to these general rules, and all treatments should be individualized. Levodopa is the drug of choice if symptoms, particularly those related to bradykinesia, seriously threaten the patient's lifestyle.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25448?source=see_link\">",
"       Selegiline",
"      </a>",
"      has mild symptomatic benefit, and it may be used in patients with early PD. Its use should be limited to patients with early disease since the symptomatic benefits are unlikely to be significant in those with more advanced PD. Nevertheless, patients should understand that there may not be much symptomatic improvement if selegiline is the initial treatment for early PD, and early follow-up and consideration of additional symptomatic therapy should be arranged. The value of selegiline for neuroprotection is unclear. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'MAO B inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/13/24791?source=see_link\">",
"       Rasagiline",
"      </a>",
"      is a newer MAO B inhibitor that has been demonstrated in randomized trials to produce a statistically significant benefit as monotherapy in PD. However, it is uncertain whether it also produces a clinically meaningful benefit that is evident to the patient. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'MAO B inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticholinergic drugs should be reserved for younger patients in whom tremor is the predominant problem. Their use in older or demented individuals and those without tremor is strongly discouraged.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"      is a relatively weak antiparkinsonian drug with low toxicity that is most useful in treating patients with early or mild PD and perhaps later when dyskinesia becomes problematic. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Anticholinergics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Amantadine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/1\">",
"      Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/2\">",
"      Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003; 60:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/3\">",
"      Albin RL, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology 2003; 60:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/4\">",
"      Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/5\">",
"      Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000; 54:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/6\">",
"      Saunders-Pullman R, Gordon-Elliott J, Parides M, et al. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999; 52:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/7\">",
"      Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drugs Ther 2005; 47:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/8\">",
"      Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999; 53:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/9\">",
"      Miller JW, Selhub J, Nadeau MR, et al. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003; 60:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/10\">",
"      Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/11\">",
"      O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, et al. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004; 19:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/12\">",
"      Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004; 63:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/13\">",
"      Toth C, Brown MS, Furtado S, et al. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008; 23:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/14\">",
"      Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010; 68:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/15\">",
"      Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/16\">",
"      Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010; 9:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/17\">",
"      Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 1996; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/18\">",
"      Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/19\">",
"      Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/20\">",
"      Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005; 20:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/21\">",
"      Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006; 63:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/22\">",
"      Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000; 284:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/23\">",
"      Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/24\">",
"      Fahn S, Bressman SB. Should levodopa therapy for Parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/25\">",
"      Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986; 43:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/26\">",
"      Markham CH, Diamond SG. Modification of Parkinson's disease by long-term levodopa treatment. Arch Neurol 1986; 43:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/27\">",
"      Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/28\">",
"      Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991; 101:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/29\">",
"      Rajput AH. The protective role of levodopa in the human substantia nigra. Adv Neurol 2001; 86:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/30\">",
"      Parkkinen L, O'Sullivan SS, Kuoppam&auml;ki M, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 2011; 77:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/31\">",
"      Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993; 8:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/32\">",
"      Dziewczapolski G, Murer G, Agid Y, et al. Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport 1997; 8:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/33\">",
"      Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/34\">",
"      Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998; 351:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/35\">",
"      Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/36\">",
"      Olanow CW, Obeso JA. Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology 2011; 77:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/37\">",
"      LeWitt PA, Dubow J, Singer C. Is levodopa toxic? Insights from a brain bank. Neurology 2011; 77:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/38\">",
"      Olanow CW. Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology 1996; 47:S210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/39\">",
"      Horn S, Stern MB. The comparative effects of medical therapies for Parkinson's disease. Neurology 2004; 63:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/40\">",
"      Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/41\">",
"      Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/42\">",
"      Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004; 329:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/43\">",
"      Thorogood M, Armstrong B, Nichols T, Hollowell J. Mortality in people taking selegiline: observational study. BMJ 1998; 317:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/44\">",
"      Olanow CW, Myllyl&auml; VV, Sotaniemi KA, et al. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998; 51:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/45\">",
"      Donnan PT, Steinke DT, Stubbings C, et al. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology 2000; 55:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/46\">",
"      Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005; 64:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/47\">",
"      Turnbull K, Caslake R, Macleod A, et al. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev 2012; 3:CD004898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/48\">",
"      P&aring;lhagen S, Heinonen E, H&auml;gglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006; 66:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/49\">",
"      Caslake R, Macleod A, Ives N, et al. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev 2009; :CD006661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/50\">",
"      Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004; 21:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/51\">",
"      Fahn S. Is levodopa toxic? Neurology 1996; 47:S184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/52\">",
"      International symposium on early dopamine agonist therapy of Parkinson's disease. Arch Neurol 1988; 45:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/53\">",
"      Marras C, Lang A. Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 2008; 70:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/54\">",
"      Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/55\">",
"      Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/56\">",
"      Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/57\">",
"      Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999; 53:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/58\">",
"      Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/59\">",
"      Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/60\">",
"      Poewe W, Rascol O, Barone P, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 2011; 77:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/61\">",
"      Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008; :CD006564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/62\">",
"      LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/63\">",
"      Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/64\">",
"      Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/65\">",
"      Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 1998; 13:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/66\">",
"      Apomorphine (Apokyn) for advanced Parkinson's Disease. Med Lett Drugs Ther 2005; 47:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/67\">",
"      Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/68\">",
"      Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 1992; 51:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/69\">",
"      Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/70\">",
"      Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002; 77:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/71\">",
"      Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/72\">",
"      Baseman DG, O'Suilleabhain PE, Reimold SC, et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/73\">",
"      Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/74\">",
"      Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/75\">",
"      Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/76\">",
"      Corvol JC, Anzouan-Kacou JB, Fauveau E, et al. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis. Arch Neurol 2007; 64:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/77\">",
"      Roth BL. Drugs and valvular heart disease. N Engl J Med 2007; 356:6.",
"     </a>",
"    </li>",
"    <li>",
"     FDA announces voluntary withdrawal of pergolide products. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108877.htm (Accessed on October 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/79\">",
"      Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/80\">",
"      Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/81\">",
"      Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/82\">",
"      Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005; 20:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/83\">",
"      Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/84\">",
"      Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007; 64:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/85\">",
"      Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/86\">",
"      Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006; 67:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/87\">",
"      Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/88\">",
"      Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/89\">",
"      Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/90\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/91\">",
"      Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/92\">",
"      Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 1998; 351:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/93\">",
"      Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004; 61:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/94\">",
"      Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003; 74:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/95\">",
"      Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000; 57:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/96\">",
"      Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 2005; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/97\">",
"      Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/98\">",
"      Duvoisin RC. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 1967; 17:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/99\">",
"      Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003; :CD003735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/100\">",
"      Lang AE. Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. Can J Neurol Sci 1984; 11:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/101\">",
"      Schwab RS, Poskanzer DC, England AC Jr, Young RR. Amantadine in Parkinson's disease. Review of more than two years' experience. JAMA 1972; 222:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/102\">",
"      Amantadine and other antiglutamate agents: management of Parkinson's disease. Mov Disord 2002; 17 Suppl 4:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/103\">",
"      Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1974; 37:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/104\">",
"      Godwin-Austen RB, Frears CC, Bergmann S, et al. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet 1970; 2:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/63/32762/abstract/105\">",
"      Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003; :CD003467.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4896 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-335F5A8ACC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32762=[""].join("\n");
var outline_f31_63_32762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMATIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Swallowing restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LEVODOPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Motor fluctuations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neurotoxic versus neuroprotective effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MAO B INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DOPAMINE AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Effectiveness of DAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adverse effects of dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Valvular heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dopaminergic dysregulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Impulse control disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMT INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ANTICHOLINERGICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      AMANTADINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      ESTROGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4896|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/30/23023\" title=\"figure 1\">",
"      Pramipexole vs levodopa complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4896|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/53/38748\" title=\"table 1\">",
"      Drug therapy Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/46/34530\" title=\"table 2\">",
"      Unified Parkinson Disease Rating Scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21784?source=related_link\">",
"      Management of comorbid problems associated with Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18857?source=related_link\">",
"      Motor fluctuations and dyskinesia in Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15863?source=related_link\">",
"      Neuroprotective therapy for Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4277?source=related_link\">",
"      Nonpharmacologic management of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22760?source=related_link\">",
"      Pathologic gambling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/8/34947?source=related_link\">",
"      Patient information: Medicines for Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/63/30708?source=related_link\">",
"      Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32105?source=related_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_63_32763="ACC AHA Prevention of critical limb ischemia";
var content_f31_63_32763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Prevention of critical limb ischemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement for the following approach to the prevention of critical limb",
"ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients at risk of CLI, defined as an diabetic patient with known lower extremity peripheral arterial disease or an ABI less than 0.4 in a nondiabetic patient, should undergo regular inspection of the feet to detect objective signs of CLI.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; The feet should be examined with shoes and socks removed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients who have been successfully treated for CLI are at relatively high risk for recurrence. They should be evaluated at least twice yearly by a vascular specialist and be given verbal and written instructions for self-surveillance for recurrence.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hirsch, AT, Haskal, ZJ, Hertzer, NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32763=[""].join("\n");
var outline_f31_63_32763=null;
var title_f31_63_32764="Lab findings in miliary TB";
var content_f31_63_32764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings in patients with miliary tuberculosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Laboratory finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maartens, 1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kim, 1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        Munt, 1971",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proudfoot, 1969",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"       <td>",
"        52*",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukopenia",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytosis or left shift",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytosis",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyponatremia",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated alkaline phosphatase",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transaminitis",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperbilirubinemia",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated ESR &gt;50",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxemia (pO2 &lt;60)",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile pyuria",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Numbers are percentages.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nesli Basgoz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32764=[""].join("\n");
var outline_f31_63_32764=null;
var title_f31_63_32765="Classification porphyrias";
var content_f31_63_32765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of the human porphyrias as hepatic or erythropoietic and as acute or cutaneous, the affected enzymes, patterns of inheritance and their major biochemical features",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Classification",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Enzyme affected",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Major biochemical findings*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Tissue site",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle2\">",
"        Urine",
"       </td>",
"       <td class=\"subtitle2\">",
"        Plasma",
"       </td>",
"       <td class=\"subtitle2\">",
"        Erythrocytes",
"       </td>",
"       <td class=\"subtitle2\">",
"        Feces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADP",
"       </td>",
"       <td>",
"        Hepatic",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Acute",
"       </td>",
"       <td>",
"        ALAD",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        ALA, coproporphyrin III",
"       </td>",
"       <td>",
"        ALA, coproporphyrin III",
"       </td>",
"       <td>",
"        Zinc protoporphyrin&nbsp;and low ALAD activity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AIP",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"       <td>",
"        Acute",
"       </td>",
"       <td>",
"        PBGD",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        ALA, PBG, coproporphyrin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Low PBGD activity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HCP",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"       <td>",
"        Acute&nbsp;and cutaneous",
"       </td>",
"       <td>",
"        CPO",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        ALA, PBG, coproporphyrin III",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Coproporphyrin III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VP",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"       <td>",
"        Acute&nbsp;and cutaneous",
"       </td>",
"       <td>",
"        PPO",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        ALA, PBG, coproporphyrin III",
"       </td>",
"       <td>",
"        Fluorescence peak at 626 nm",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Coproporphyrin III&nbsp;and protoporphyrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCT",
"       </td>",
"       <td>",
"        Hepatic",
"       </td>",
"       <td>",
"        Cutaneous",
"       </td>",
"       <td>",
"        UROD",
"       </td>",
"       <td>",
"        Autosomal dominant",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Uroporphyrin&nbsp;and hepta-carboxyl-porphyrin",
"       </td>",
"       <td>",
"        Uroporphyrin&nbsp;and hepta-carboxyl-porphyrin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Isocoproporphyrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HEP",
"       </td>",
"       <td>",
"        Hepatic",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Cutaneous",
"       </td>",
"       <td>",
"        UROD",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        Uroporphyrin&nbsp;and hepta-carboxyl-porphyrin",
"       </td>",
"       <td>",
"        Uroporphyrin and hepta-carboxyl-porphyrin",
"       </td>",
"       <td>",
"        Zinc protoporphyrin&nbsp;and low UROD activity",
"       </td>",
"       <td>",
"        Isocoproporphyrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CEP",
"       </td>",
"       <td>",
"        Erythro-poietic",
"       </td>",
"       <td>",
"        Cutaneous",
"       </td>",
"       <td>",
"        UROS",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td>",
"        Uroporphyrin I and coproporphyrin I",
"       </td>",
"       <td>",
"        Uroporphyrin I and coproporphyrin I",
"       </td>",
"       <td>",
"        Uroporphyrin I and coproporphyrin I",
"       </td>",
"       <td>",
"        Coproporphyrin I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EPP&nbsp;&mdash; classic form",
"       </td>",
"       <td>",
"        Erythro-poietic",
"       </td>",
"       <td>",
"        Cutaneous",
"       </td>",
"       <td>",
"        FECH",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Protoporphyrin",
"       </td>",
"       <td>",
"        Free protoporphyrin",
"       </td>",
"       <td>",
"        Protoporphyrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EPP&nbsp;&mdash; variant form",
"       </td>",
"       <td>",
"        Erythro-poietic",
"       </td>",
"       <td>",
"        Cutaneous",
"       </td>",
"       <td>",
"        ALAS2",
"       </td>",
"       <td>",
"        X-linked recessive",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Protoporphyrin",
"       </td>",
"       <td>",
"        Free and zinc protoporphyrin",
"       </td>",
"       <td>",
"        Protoporphyrin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ADP: ALA dehydratase porphyria; AIP: acute intermittent porphyria; HCP: hereditary coproporphyria; VP: variegate porphyria; PCT: porphyria cutanea tarda; HEP: hepatoerythropoietic porphyria; CEP: congenital erythropoietic porphyria; EPP: erythropoietic protoporphyria; ALAD: ALA dehydratase; PBGD: porphobilinogen deaminase; CPO: coproporphyrinogen oxidase; PPO: protoporphyrinogen oxidase; UROD: uroporphyrinogen decarboxylase; UROS: uroporphyrinogen III synthase; FECH: ferrochelatase; ALAS2: ALA-synthase 2; ALA: delta-aminolevulinic acid; PBG: porphobilinogen.",
"    <div class=\"footnotes\">",
"     *&nbsp;Increases of importance for diagnosis in most cases.",
"     <br>",
"      &bull;&nbsp;These hepatic porphyrias also have erythropoietic features, including increases in erythrocyte zinc protoporphyrin.",
"      <br>",
"       &Delta;&nbsp;UROD inhibition in PCT is mostly acquired, but an inherited deficiency of the enzyme predisposes in familial (type 2) disease.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Karl Anderson, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32765=[""].join("\n");
var outline_f31_63_32765=null;
var title_f31_63_32766="Piper forceps";
var content_f31_63_32766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Piper forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32766=[""].join("\n");
var outline_f31_63_32766=null;
var title_f31_63_32767="Carcinoid ileum UGI";
var content_f31_63_32767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carcinoid tumor of the ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 219px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel follow through examination shows a polypoid eccentric mass arising from the wall of the terminal ileum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_63_32767=[""].join("\n");
var outline_f31_63_32767=null;
